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A B S T R A C T 
Background 
Approximately 2.5% of all hospitalisations in people with cirrhosis are for spontaneous bacterial peritonitis (SBP). Antibiotics, in 
addition to supportive treatment (fluid and electrolyte balance, treatment of shock), form the mainstay treatments of SBP. Various 
antibiotics are available for the treatment of SBP, but there is uncertainty regarding the best antibiotic for SBP. 
Objectives 
To compare the benefits and harms of different antibiotic treatments for spontaneous bacterial peritonitis (SBP) in people with 
decompensated liver cirrhosis. 
Search methods 
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical 
Trials Registry Platform, and trials registers until November 2018 to identify randomised clinical trials on people with cirrhosis and 
SBP. 
Selection criteria 
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in adults with cirrhosis and SBP. 
We excluded randomised clinical trials in which participants had previously undergone liver transplantation. 
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Data collection and analysis 
Two review authors independently identified eligible trials and collected data. The outcomes for this review included mortality, serious 
adverse events, any adverse events, resolution of SBP, liver transplantation, and other decompensation events. We performed a network 
meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio with 95% credible 
intervals (CrIs) based on an available-case analysis, according to the National Institute of Health and Care Excellence (NICE) Decision 
Support Unit guidance. 
Main results 
We included a total of 12 trials (1278 participants; 13 antibiotics) in the review. Ten trials (893 participants) were included in one or 
more outcomes in the review. The trials that provided the information included patients having cirrhosis with or without other features 
of decompensation of varied aetiologies. The follow-up in the trials ranged from one week to three months. All the trials were at high 
risk of bias. Only one trial was included under each comparison for most of the outcomes. Because of these reasons, there is very low 
certainty in all the results. The majority of the randomised clinical trials used third-generation cephalosporins, such as intravenous 
ceftriaxone, cefotaxime, or ciprofloxacin as one of the interventions. 
Overall, approximately 75% of trial participants recovered from SBP and 25% of people died within three months. There was no 
evidence of difference in any of the outcomes for which network meta-analysis was possible: mortality (9 trials; 653 participants), 
proportion of people with any adverse events (5 trials; 297 participants), resolution of SBP (as per standard definition, 9 trials; 873 
participants), or other features of decompensation (6 trials; 535 participants). The effect estimates in the direct comparisons (when 
available) were very similar to those of network meta-analysis. For the comparisons where network meta-analysis was not possible, there 
was no evidence of difference in any of the outcomes (proportion of participants with serious adverse events, number of adverse events, 
and proportion of participants requiring liver transplantation). Due to the wide CrIs and the very low-certainty evidence for all the 
outcomes, significant benefits or harms of antibiotics are possible. 
None of the trials reported health-related quality of life, number of serious adverse events, or symptomatic recovery from SBP. 
Funding: the source of funding for two trials were industrial organisations who would benefit from the results of the trial; the source 
of funding for the remaining 10 trials was unclear. 
Authors’ conclusions 
Short-term mortality after SBP is about 25%. There is significant uncertainty about which antibiotic therapy is better in people with 
SBP. 
We need adequately powered randomised clinical trials, with adequate blinding, avoiding post-randomisation dropouts (or performing 
intention-to-treat analysis), and using clinically important outcomes, such as mortality, health-related quality of life, and adverse events. 
P L A I N L A N G U A G E S U M M A R Y 
Antibiotic treatment for spontaneous bacterial peritonitis in people with advanced liver disease 
What is the aim of this Cochrane Review? 
To find out the best available antibiotic for spontaneous bacterial peritonitis (fluid collection in the tummy (abdomen), infected with 
bacteria) in people with advanced liver disease (liver cirrhosis, or late stage scarring of the liver with complications). The abnormal 
buildup of fluid in people with liver cirrhosis is called ascites. Sometimes, this fluid may get infected with bacteria, with no obvious source 
of infection. This is called ’spontaneous bacterial peritonitis’. The main treatment of spontaneous bacterial peritonitis is antibiotics, but 
it is unclear which antibiotic is best for treating it. The authors collected and analysed all relevant studies to answer this question and 
found 12 randomised clinical trials (participants receive the treatment based on methods similar to a coin toss; this is to ensure that the 
people who receive the different treatments are similar in all aspects except the treatment, so that any differences in the results between 
the treatments can be attributed to the treatment rather than differences in the type of people who received the treatment). During 
the analysis of data, authors used standard Cochrane techniques, which allows comparison of two treatments at a time. Authors also 
used advanced techniques, that allows comparison of many treatments at the same time (usually referred as ’network meta-analysis’ or 
’multiple treatment comparisons’). The aim is to gather reliable evidence on the relative benefits and harms of the different antibiotics. 
Date of literature search 









None of the studies were conducted without flaws, and because of the very low certainty in the results, the authors cannot suggest 
which antibiotic, given alone or in combination to remove the bacteria from one’s tummy, is better or worse than other antibiotics in 
the treatment of spontaneous bacterial peritonitis. 
The funding source was unclear in 10 studies; industrial organisations funded two studies. 
What was studied in the review? 
This review studied people, of any sex, age, and origin, with advanced liver disease due to various causes, and who had developed 
spontaneous bacterial peritonitis. People were administered different antibiotics for the treatment of spontaneous bacterial peritonitis. 
The authors excluded studies with liver transplanted participants and bacterial peritonitis due to other causes. The participants’ age, 
when reported, ranged from 42 to 60 years. The number of females, when reported, ranged from 18 to 42 out of 100. The administered 
antibiotic groups were cephalosporins, penicillins, and quinolones. The review authors wanted to gather and analyse data on death, 
quality of life, serious and non-serious complications, time to liver transplantation (replacement of a diseased liver with a healthy one), 
time until disappearance of spontaneous bacterial peritonitis, and disappearance of symptoms. 
What were the main results of the review? 
The 12 studies included a small number of participants (1278 participants). The study data were sparse; 10 studies with 893 participants 
provided data for analyses. Follow-up in the trials ranged from one week to three months. The review shows the following. 
- Out of the 13 different antibiotics compared in the trials, ceftriaxone and cefotaxime administered into the vein, were most commonly 
used. 
- The type of antibiotic provided may make no difference to the number or percentage of people with serious complications or with 
any complications; number of (any) complications per person; percentage of people undergoing liver transplantation; or who recovered 
from spontaneous bacterial peritonitis as per laboratory tests, or other complications of liver cirrhosis. 
- Twenty-five out of every 100 people died within three months, and 75 out of every 100 people recovered from spontaneous bacterial 
peritonitis. 
- None of the trials reported health-related quality of life, number of serious adverse events, or symptomatic recovery from spontaneous 
bacterial peritonitis. 
- We have very low confidence in the overall results. Whether some antibiotics may cause important or less important benefits or harms 
compared to others when given to people with advanced liver disease and spontaneous bacterial peritonitis is questionable. 
- We need data from trials of proper design and quality in order to be able to clarify the best antibiotic for spontaneous bacterial 
peritonitis. 








(0.09 to 5.90) 
Network est imate 
263 per 1000 201 per 1000 
(24 to 1000) 
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation] 
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis 
Patient or population: people with cirrhosis and spontaneous bacterial peritonit is 
Settings: secondary or tert iary care 
Intervention: various intervent ions 
Comparison: cef triaxone 
Follow-up period: 1 week to 3 months 
Network geometry plots: Figure 1 
Interventions Relative effect 
(95% CrI) 
Anticipated absolute effect* (95% CrI) Certainty of evidence Ranking* * 
Ceftriaxone Various interventions Difference 
All- cause mortality 
Total studies: 7 
Total participants: 458 
Cefotaxime 
(1 RCT; 37 part icipants) 
HR 0.56 
(0.11 to 2.28) 
Network est imate 
263 per 1000 146 per 1000 
(28 to 599) 
117 fewer per 1000 
(235 f ewer to 336 more) 
Very lowa,b,c -
Ciprofloxacin 
(1 RCT; 35 part icipants) 
HR 0.65 
(0.12 to 2.72) 
Network est imate 
263 per 1000 171 per 1000 
(31 to 717) 
92 fewer per 1000 
(232 f ewer to 454 more) 
Very lowa,b,c -
Ceftazidime 
(No direct RCT) 
HR 1.15 
(0.17 to 6.37) 
Network est imate 
263 per 1000 301 per 1000 
(45 to 1000) 
38 more per 1000 
(218 f ewer to 737 more) 
Very lowa,b,c -
Very lowa,b,c -Amikacin 
(No direct RCT) 
62 fewer per 1000 











































































































































Health- related quality of life 
None of the t rials reported this outcome 
Serious adverse events (proportion of participants) 
None of the t rials with cef triaxone as control group reported this outcome 
Serious adverse events (number of events per participant) 
None of the t rials reported this outcome 
Adverse events (proportion of participants) 
Total studies: 5 
Total participants: 297 
Cefotaxime 
(1 RCT; 37 part icipants) 
OR 0.64 
(0.15 to 2.62) 
Network est imate 
44 per 1000 
(10 to 157) 
23 fewer per 1000 
(56 f ewer to 91 more) 
Very lowa,b,c -
HR 0.56 
(0.09 to 2.93) 
Network est imate 
67 per 1000 
Cefixime 
(1 RCT; 38 part icipants) 
Cefonicid 
(1 RCT; 60 part icipants) 
M eropenem plus dap­
tomycin 
(No direct RCT) 
Ofloxacin 
(No direct RCT) 
HR 1.26 
(0.26 to 6.90) 
Network est imate 
263 per 1000 331 per 1000 
(68 to 1000) 
68 more per 1000 
(195 f ewer to 737 more) 
HR 1.30 
(0.52 to 3.24) 
Network est imate 
263 per 1000 341 per 1000 
(138 to 853) 
78 more per 1000 
(126 f ewer to 590 more) 
HR 0.64 
(0.05 to 6.13) 
Network est imate 
169 per 1000 
(14 to 1000) 
94 fewer per 1000 
(249 f ewer to 737 more) 
147 per 1000 
(23 to 770) 
116 fewer per 1000 
(240 f ewer to 507 more) 
Very lowa,b,c -
263 per 1000 











































































































































(0.24 to 4.16) 
Network est imate 
67 per 1000 68 per 1000 
(17 to 229) 
1 more per 1000 
(50 f ewer to 162 more) 
Very lowa,b,c -
OR 1.97 
(0.38 to 10.18) 
Network est imate 
67 per 1000 123 per 1000 
(27 to 421) 
57 more per 1000 
(40 f ewer to 354 more) 
Very lowa,b,c -
OR 0.69 
(0.04 to 10.94) 
Network est imate 
67 per 1000 47 per 1000 
(3 to 439) 
Very lowa,b,c -
Cefonicid 
(1 RCT; 60 part icipants) 
OR 1.00 
(0.10 to 10.16) 
Network est imate 
67 per 1000 67 per 1000 
(7 to 420) 
-
M eropenem plus dap­
tomycin 
(No direct RCT) 
OR 1.20 
(0.10 to 13.53) 
Network est imate 
67 per 1000 79 per 1000 
(7 to 491) 
-
Adverse events (number of events per participant) 
None of the t rials with cef triaxone as control group reported this outcome 
Liver transplantation 
None of the t rials with cef triaxone as control group reported this outcome 
Spontaneous bacterial peritonitis (symptomatic) 
None of the t rials reported this outcome 
Spontaneous bacterial peritonitis (as per definition used for spontaneous bacterial peritonitis) 
Total studies: 7 








































































































































(1 RCT; 35 part icipants) 
Ceftazidime 
(No direct RCT) 
Amikacin 
(No direct RCT) 
20 fewer per 1000 
(64 f ewer to 372 more) 
0 fewer per 1000 
(60 f ewer to 354 more) 
12 more per 1000 








(No direct RCT) 
HR 1.12 
(0.45 to 2.70) 
Network est imate 
733 per 1000 825 per 1000 
(330 to 1000) 
91 more per 1000 
(404 f ewer to 267 more) 
Very lowa,b,c -
Other features of decompensation (per participant) 
Total studies: 5 
Total participants: 360 
Cefotaxime 
(1 RCT; 37 part icipants) 
Rate ratio 1.22 
(0.43 to 3.53) 
Network est imate 
368 per 1000 449 per 1000 
(160 to 1301) 
80 more per 1000 
(209 f ewer to 933 more) 
Very lowa,b,c -
HR 1.29 
(0.43 to 3.92) 
Network est imate 
Cefotaxime 
(1 RCT; 37 part icipants) 
Ciprofloxacin 
(2 RCT; 275 part ici­
pants) 
Ceftazidime 
(No direct RCT) 
Amikacin 
(No direct RCT) 
Cefixime 
(1 RCT; 38 part icipants) 
M eropenem plus dap­
tomycin 
(No direct RCT) 
HR 0.90 
(0.42 to 1.86) 
Network est imate 
733 per 1000 661 per 1000 
(308 to 1000) 
73 fewer per 1000 
(425 f ewer to 267 more) 
HR 0.93 
(0.69 to 1.25) 
Network est imate 
733 per 1000 679 per 1000 
(504 to 916) 
54 fewer per 1000 
(230 f ewer to 183 more) 
HR 0.97 
(0.55 to 1.72) 
Network est imate 
733 per 1000 713 per 1000 
(403 to 1000) 
21 fewer per 1000 
(330 f ewer to 267 more) 
HR 0.54 
(0.17 to 1.62) 
Network est imate 
733 per 1000 393 per 1000 
(126 to 1000) 
340 fewer per 1000 
(608 f ewer to 267 more) 
HR 0.78 
(0.32 to 1.90) 
Network est imate 
575 per 1000 
(232 to 1000) 
159 fewer per 1000 
(501 f ewer to 267 more) 
211 more per 1000 
(419 f ewer to 267 more) 
Very lowa,b,c -
733 per 1000 
944 per 1000 
(315 to 1000) 









































































































































(1 RCT; 35 part icipants) 
Ceftazidime 
(No direct RCT) 
Amikacin 
(No direct RCT) 
M eropenem plus dap­
tomycin 
(No direct RCT) 
Ofloxacin 
(No direct RCT) 
Rate ratio 1.01 
(0.32 to 3.16) 
Network est imate 
368 per 1000 373 per 1000 
(119 to 1164) 
4 more per 1000 
(249 f ewer to 795 more) 
Very lowa,b,c 
Rate ratio 1.43 
(0.40 to 5.19) 
Network est imate 
368 per 1000 527 per 1000 
(147 to 1911) 
159 more per 1000 
(222 f ewer to 1542 
more) 
Very lowa,b,c 
Rate ratio 1.28 
(0.11 to 15.66) 
Network est imate 
368 per 1000 471 per 1000 
(40 to 5769) 
103 more per 1000 
(329 f ewer to 5400 
more) 
Very lowa,b,c 
Rate ratio 2.19 
(0.49 to 9.49) 
Network est imate 
368 per 1000 807 per 1000 
(179 to 3495) 
438 more per 1000 
(189 f ewer to 3127 
more) 
Very lowa,b,c 
Rate ratio 1.12 
(0.31 to 4.09) 
Network est imate 
368 per 1000 412 per 1000 
(113 to 1508) 
44 more per 1000 







* Ant icipated absolute ef fect. Anticipated absolute ef fect compares two risks by calculat ing the dif ference between the risks of the intervent ion group with the weighted 
median risk of the control group 
* *Ranking is not provided as the median rank was not 1 f or at least one of the ranking posit ions f or each intervent ion f or the outcome 
CrI: credible interval; HR: hazard rat io; OR: odds rat io; RCT : randomised clinical t rial 
GRADE Working Group grades of evidence 
High certainty: we are very conf ident that the t rue ef fect l ies close to that of the est imate of the ef fect. 
Moderate certainty: we are moderately conf ident in the ef fect est imate; the t rue ef fect is l ikely to be close to the est imate of the ef fect, but there is a possibility that it is 
substant ially dif ferent. 
Low certainty: our conf idence in the ef fect est imate is l im ited; the t rue ef fect may be substant ially dif ferent f rom the est imate of the ef fect. 
Very low certainty: we have very l it t le conf idence in the ef fect est imate; the t rue ef fect is l ikely to be substant ially dif ferent f rom the est imate of ef fect 
a The t rial(s) included in the analysis was/ were at high risk of bias (downgraded 1 level).
 
bThe sample size was small (downgraded 1 level).
 









































































































































Figure 1. The network plots showing the outcomes for which network meta-analysis was performed. The 
size of the node (circle) provides a measure of the number of trials in which the particular intervention was 
included as one of the intervention groups. The thickness of the line provides a measure of the number of 
direct comparisons between two nodes (interventions). 
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B A C K G R O U N D 
Description of the condition 
Liver cirrhosis 
The liver is a complex organ with multiple functions, including 
metabolism of carbohydrates, fats, proteins, and drugs; it also has 
synthetic, storage, digestive, excretory, and immunological func-
tions (Read 1972). Liver cirrhosis is a liver disease in which the 
normal microcirculation, the gross vascular anatomy, and the hep­
atic architecture have been variably destroyed and altered, with 
fibrous septa surrounding regenerated or regenerating parenchy­
mal nodules (Tsochatzis 2014; NCBI 2018a). The major causes 
of liver cirrhosis include excessive alcohol consumption, viral hep­
atitis, non-alcohol-related fatty liver disease, autoimmune liver 
disease, and metabolic liver disease (Williams 2014; Ratib 2015; 
Setiawan 2016). The global prevalence of liver cirrhosis is difficult 
to estimate as most estimates correspond to chronic liver disease 
(which includes liver fibrosis and liver cirrhosis). In studies from 
the USA, the prevalence of chronic liver disease varies between 
0.3% and 2.1% (Scaglione 2015; Setiawan 2016); in the UK, the 
prevalence was 0.1% in one study (Fleming 2008). In 2010, liver 
cirrhosis caused an estimated 2% of all global deaths, equivalent to 
one million deaths (Mokdad 2014). There is an increasing trend 
of cirrhosis-related deaths in some countries, like the UK, while 
there is a decreasing trend in other countries, for example France 
(Mokdad 2014; Williams 2014). The major cause of complica­
tions and deaths in people with liver cirrhosis is due to the develop­
ment of clinically significant portal hypertension - hepatic venous 
pressure gradient at least 10 mmHg (de Franchis 2015). Some 
of the clinical features of decompensation include jaundice, coag­
ulopathy, ascites, variceal bleeding, hepatic encephalopathy, and 
renal failure (de Franchis 2015; McPherson 2016; EASL 2018). 
Decompensated cirrhosis is the most common indication for liver 
transplantation (Merion 2010; Adam 2012). 
Spontaneous bacterial peritonitis (SBP) 
Ascites is accumulation of free fluid in the abdomen (peritoneal 
cavity) (NCBI 2018b), and is a feature of liver decompensation 
(Tsochatzis 2017; EASL 2018). Approximately 20% of people 
with cirrhosis have ascites (D’Amico 2014). Approximately 1% to 
4% of people with cirrhosis develop ascites each year (D’Amico 
2006; D’Amico 2014). Ascites is the first sign of liver decompen­
sation in about one-third of people with compensated liver cir­
rhosis (D’Amico 2014). When the ascitic fluid is infected with 
bacteria, it is called ’spontaneous bacterial peritonitis’ (SBP). Due 
to the poor sensitivity of ascitic fluid culture, SBP is diagnosed 
by a polymorphonuclear (PMN) leukocyte count of more than 
250 per mm3 in the ascitic fluid (Rimola 2000; EASL 2018). In 
the presence of haemorrhagic ascites (ascites with red blood cell 
count of more than 10,000 per mm3), one PMN leukocyte count 
should be subtracted for every 250 red blood cells to account for 
the presence of blood in the ascitic fluid (Rimola 2000). People 
with SBP may or may not display symptoms of peritonitis, such 
as abdominal pain fever,chills, and hypotension (Rimola 2000; 
Nousbaum 2007; EASL 2010). 
The overall incidence and prevalence of SBP in people with cir­
rhosis is difficult to estimate. Approximately 2.5% of all hospital­
isations in people with cirrhosis are for SBP (Devani 2017). The 
prevalence of SBP in patients with cirrhosis and ascites under­
going paracentesis varies from 0.5% to 8.7% (Nousbaum 2007; 
Castellote 2008; Khan 2009; Cadranel 2013). The incidence of 
SBP in people with decompensated liver cirrhosis is about 20% 
over a period of one to 12 months (Saab 2009). 
The short-term mortality (that is, death within 30 days of diag­
nosis or death in hospital) after SBP is about 15% to 40% (Khan 
2009; Tandon 2011; Devani 2017). In addition, SBP is associated 
with significant resource utilisation; a study conducted in the USA 
showed that the average length of hospital stay was approximately 
six days and the average hospital costs per patient were approxi­
mately USD 17,000 (Devani 2017). 
Pathophysiology of SBP 
Increased bacterial translocation (gut bacteria or bacterial prod­
ucts migrating outside the intestinal lumen) and decreased local 
and systemic immune responses in patients having cirrhosis are 
believed to be the cause of SBP (Bernardi 2010). 
Description of the intervention 
Antibiotics, in addition to supportive treatment (fluid and elec­
trolyte balance, treatment of shock) form the mainstay treatment 
of SBP. There are various classes of antibiotics available for the 
treatment of SBP. If bacteria can be cultured from the ascitic fluid, 
antibiotic therapy can be based on the susceptibility of the bacteria 
to different antibiotics (EASL 2010; Runyon 2013; EASL 2018). 
However, bacteria can be cultured only in 40% to 60% of peo­
ple with SBP (Rimola 2000; EASL 2010). Therefore, empirical 
antibiotic treatment is used in the majority of people with SBP 
(EASL 2010; Runyon 2013; EASL 2018). The major classes of 
empirical antibiotics used in the treatment of SBP include third­
generation cephalosporins, such as ceftriaxone, cefotaxime, and ­
less commonly - penicillins, such as amoxicillin/clavulanic acid, 
and fluoroquinolones, such as ciprofloxacin (in people who have 
not taken fluoroquinolones for prophylaxis of SBP) (EASL 2010; 
Runyon 2013; EASL 2018). 
How the intervention might work 
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Different antibiotic classes have different mechanisms of action to 
kill bacteria (bactericidal effect) or reduce their growth (bacterio­
static effect). Penicillins and cephalosporins inhibit bacterial cell 
wall synthesis (Yocum 1980; Yotsuji 1988). Fluoroquinolones are 
type II topoisomerase inhibitors; type II topoisomerases at appro­
priate levels are required for normal cellular processes, and alter­
ing their levels leads to bacterial cell death (Aldred 2014). Other 
antibiotics act via bacteriostatic effects. 
Why it is important to do this review 
SBP is associated with significant short-term mortality (Khan 
2009; Tandon 2011; Devani 2017). It is important to provide 
optimal empirical treatment to people with SBP while waiting for 
the results of ascitic fluid culture and sensitivity (susceptibility of 
bacteria to the specific antibiotic) to improve their survival. Bac­
teria can be cultured only in 40% to 60% of people with SBP 
(Rimola 2000; EASL 2010). Several different antibiotic treatments 
are available, but their relative efficacy and the optimal combina­
tion are not known. There has been one Cochrane Review on the 
role of antibiotics in patients with cirrhosis and SBP (Chavez-Tapia 
2009); however, there have been no previous network meta-anal­
yses on the topic. Network meta-analysis allows for a combina­
tion of direct and indirect evidence, and the ranking of different 
interventions for different outcomes (Salanti 2011; Salanti 2012). 
With this systematic review and network meta-analysis, we aim 
to provide the best level of evidence for the benefits and harms of 
different antibiotic treatments for SBP in people with decompen­
sated liver cirrhosis. 
O B J E C T I V E S 
To compare the benefits and harms of different antibiotic treat­
ments for spontaneous bacterial peritonitis (SBP) in people with 
decompensated liver cirrhosis. 
M E T H O D S 
Criteria for considering studies for this review 
Types of studies 
We considered only randomised clinical trials for this network 
meta-analysis, irrespective of language, publication status, or date 
of publication. We excluded studies with a quasi-randomised de­
sign or non-randomised design because of the risk of bias in such 
studies. Inclusion of indirect observational evidence could weaken 
our network meta-analysis, but this could also be viewed as a 
strength for assessing rare adverse events. It is well established that 
exclusion of non-randomised studies increases the focus on po­
tential benefits and reduces the focus on the risks of serious ad­
verse events and those of any adverse events. However, due to 
the exponentially increased amount of work required for non-ran­
domised studies, we planned to register and perform a new sys­
tematic review and meta-analysis of non-randomised studies for 
adverse events, if there was uncertainty in the balance of benefits 
and harms of effective treatment(s). We did not perform this be­
cause of the findings of the review. 
Types of participants 
We included randomised clinical trials with adult participants with 
decompensated liver cirrhosis, who are undergoing treatment for 
spontaneous bacterial peritonitis (SBP). We excluded randomised 
clinical trials in which participants have previously undergone liver 
transplantation, have SBP due to other causes, or have secondary 
peritonitis (i.e. peritonitis due to hollow viscus perforation or in­
flammation of other intra-abdominal organs, such as appendicitis 
or pancreatitis). 
Types of interventions 
We included any of the following different antibiotic interventions 




• Other classes of antibiotics 
We did not include trials evaluating interventions targeted at fluid 
and electrolyte balance, or the treatment of shock. However, we 
included trials in which such cointerventions are administered 
equally in all the intervention arms. 
We evaluated the plausibility of the transitivity assumption (the 
assumption that participants included in the different trials with 
different treatments can be considered to be a part of a multi­
arm randomised clinical trial and could potentially have been ran­
domised to any of the interventions) (Salanti 2012), by looking at 
the inclusion and exclusion criteria in the studies. In other words, 
any participant that meets the inclusion criteria is, in principle, 
equally likely to be randomised to any of the above eligible in­
terventions. This necessitates that information on potential effect 
modifiers, such as the presence of other features of decompensa­
tion (hepatorenal syndrome, hepatic encephalopathy, or variceal 
bleeding) are the same across trials. Since, there was no concern 
about the transitivity assumption, we did not perform a separate 
meta-analysis for people with cirrhosis and SBP versus without 
other features of decompensation. 
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Types of outcome measures 
Primary outcomes 
• All-cause mortality at maximal follow-up (time to death) 
• Health-related quality of life using a validated scale, such as 
the EQ-5D or 36-Item Short Form Health Survey (SF-36) 
(EuroQol 2018; Optum 2018), at maximal follow-up 
• Serious adverse events (during or within 6 months after 
cessation of the intervention). We defined a serious adverse event 
as any event that would increase mortality; is life-threatening; 
requires hospitalisation; results in persistent or significant 
disability; is a congenital anomaly/birth defect; or any important 
medical event that might jeopardise the person or require 
intervention to prevent it (ICH-GCP 1997). However, none of 
the authors defined serious adverse events. Therefore, we used 
the definitions provided by trial authors for serious adverse 
events (as indicated in the protocol). 
◦ Proportion of participants with one or more serious 
adverse event(s) 
◦ Number of serious adverse events per participant 
Secondary outcomes 
• Any adverse event (during or within 6 months after 
cessation of the intervention): we defined an adverse event as any 
untoward medical occurrence, not necessarily having a causal 
relationship with the intervention, but resulting in a dose 
reduction or discontinuation of intervention (any time after 
commencement of the intervention) (ICH-GCP 1997). 
However, none of the authors defined ’adverse event’. Therefore, 
we used the definitions provided by trial authors for adverse 
events (as indicated in the protocol). 
◦ Proportion of participants with one or more adverse 
event 
◦ Number of any adverse events per participant 
• Time to liver transplantation (maximal follow-up) 
• Time to resolution of spontaneous bacterial peritonitis 
(SBP) (however defined by study authors at maximal follow-up) 
◦ Symptomatic recovery 
◦ Recovery according to definitions used for SBP 
• Number of other decompensation episodes (maximal 
follow-up) 
Exploratory outcomes 
• Length of hospital stay (all hospital admissions until 
maximal follow-up) 
• Number of days of lost work (in people who work) 
(maximal follow-up) 
• Treatment costs (including the cost of the treatment and 
any resulting complications) 
We have chosen outcomes based on their importance to patients in 
a survey related to research priorities for people with liver diseases 
(Gurusamy 2019), based on feedback of the patient and public 
representative of this project, and based on an online survey about 
the outcomes promoted through the Cochrane Consumer Net­
work. 
Search methods for identification of studies 
Electronic searches 
We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Em­
base Ovid, and Science Citation Index Expanded (Web of Sci­
ence) from inception to 10 November 2018, without applying 
any language restrictions (Royle 2003). We searched for all pos­
sible comparisons formed by the interventions of interest. To 
identify further ongoing or completed trials, we also searched 
clinicaltrials.gov, and the World Health Organization Interna­
tional Clinical Trials Registry Platform (apps.who.int/trialsearch/) 
which included various trial registers, including ISRCTN and 
ClinicalTrials.gov on 10 November 2018. We also searched the 
European Medical Agency ( EMA) ( www.ema.europa.eu/ema/), 
and US Food and Drug Administration ( FDA) registries ( 
www.fda.gov), for randomised clinical trials on 10 November 
2018. The search strategies are provided in Appendix 1. 
Searching other resources 
We searched the references of the identified trials and the existing 
Cochrane Review on antibiotic treatments in liver cirrhosis to 
identify additional trials for inclusion (Chavez-Tapia 2009). 
Data collection and analysis 
Selection of studies 
Two review authors (KG and LP) independently identified trials 
for inclusion by screening the titles and abstracts, and sought full­
text articles for any references identified by at least one of the re­
view authors for potential inclusion. We selected trials for inclu­
sion based on the full-text articles. We provided the list of refer­
ences that we excluded and the reasons for their exclusion in the 
’Characteristics of excluded studies’ table. We also planned to list 
any ongoing trials identified primarily through the search of the 
clinical trial registers for further follow-up. We resolved any dis­
crepancies through discussion. 
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Data extraction and management 
Two review authors (KG and LP) independently extracted the 
following data in a piloted Microsoft Excel-based data extraction 
form (after translation of non-English articles). 
• Outcome data (for each outcome and for each intervention 
group whenever applicable) 
◦ number of participants randomised 
◦ number of participants included for the analysis 
◦ number of participants with events for binary 
outcomes, mean and standard deviation for continuous 
outcomes, number of events and the mean follow-up period for 
count outcomes, and number of participants with events and the 
mean follow-up period for time-to-event outcomes 
◦ natural logarithm of hazard ratio and its standard 
error, if this was reported, rather than the number of participants 
with events and the mean follow-up period for time-to-event 
outcomes 
◦ definition of outcomes or scale used, if appropriate 
• Data on potential effect modifiers 
◦ participant characteristics, such as age, sex, presence of 
other features of decompensation (hepatorenal syndrome, 
hepatic encephalopathy, and variceal bleeding), the aetiology for 
cirrhosis, and the interval between diagnosis of SBP and 
treatment 
◦ details of the intervention and control (including dose, 
frequency, and duration) 
◦ length of follow-up 
◦ information related to ’Risk of bias’ assessment (please 
see below) 
• Other data 
◦ year and language of publication 
◦ country in which the participants were recruited 
◦ year(s) in which the trial was conducted 
◦ inclusion and exclusion criteria 
We collected outcomes at maximum follow-up, but also at short-
term (up to 3 months) and medium-term (from 3 months to 5 
years), if applicable. 
We attempted to contact the trial authors in the case of unclear or 
missing information. If there was any doubt as to whether trials 
shared the same participants, completely or partially (by identi­
fying common authors and centres), we planned to contact the 
trial authors to clarify whether the trial report was duplicated. We 
resolved any differences in opinion through discussion. 
Assessment of risk of bias in included studies 
We followed the guidance in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011) to assess the risk of bias in 
included trials. Specifically, we assessed sources of bias as defined 
below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008; 
Savovi 2012a; Savovi 2012b; Savovi 2018). 
Allocation sequence generation 
• Low risk of bias: the study authors performed sequence 
generation using computer random number generation or a 
random number table. Drawing lots, tossing a coin, shuffling 
cards, and throwing dice are adequate if performed by an 
independent person not otherwise involved in the study. In 
general, we classified the risk of bias as low if the method used 
for allocation concealment suggested that it was extremely likely 
that the sequence was generated randomly (for example, use of 
interactive voice response system). 
• Unclear risk of bias: the study authors did not specify the 
method of sequence generation. 
• High risk of bias: the sequence generation method was not 
random. We excluded such quasi-randomised studies. 
Allocation concealment 
• Low risk of bias: the participant allocations could not have 
been foreseen in advance of, or during, enrolment. A central and 
independent randomisation unit controlled allocation. The 
investigators were unaware of the allocation sequence (e.g. if the 
allocation sequence was hidden in sequentially numbered, 
opaque, and sealed envelopes). 
• Unclear risk of bias: the study authors did not describe the 
method used to conceal the allocation so that the intervention 
allocations may have been foreseen before, or during, enrolment. 
• High risk of bias: it is likely that the investigators who 
assigned the participants knew the allocation sequence. We 
excluded such quasi-randomised studies. 
Blinding of participants and personnel 
• Low risk of bias: blinding of participants and key study 
personnel was ensured, and it was unlikely that the blinding 
could have been broken; or there was rarely no blinding or 
incomplete blinding, but the review authors judged that the 
outcome was not likely to be influenced by lack of blinding. 
• Unclear risk of bias: insufficient information to permit a 
judgement of ’low risk’ or ’high risk’; or the trial did not address 
this outcome. 
• High risk of bias: no blinding or incomplete blinding, and 
the outcome was likely to be influenced by lack of blinding; or 
blinding of key study participants and personnel was attempted, 
but it was likely that the blinding could have been broken, and 
the outcome was likely to be influenced by lack of blinding. 
Blinded outcome assessment 
• Low risk of bias: blinding of outcome assessment was 
ensured, and it was unlikely that the blinding could have been 
broken; or rarely no blinding of outcome assessment, but the 
review authors judged that the outcome measurement was not 
likely to be influenced by lack of blinding. 
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• Unclear risk of bias: insufficient information to permit a 
judgement of ’low risk’ or ’high risk’; or the trial did not address 
this outcome. 
• High risk of bias: any of the following - no blinding of 
outcome assessment, and the outcome measurement was likely 
to be influenced by lack of blinding; or blinding of outcome 
assessment, but likely that the blinding could have been broken, 
and the outcome measurement was likely to be influenced by 
lack of blinding. 
Incomplete outcome data 
• Low risk of bias: missing data were unlikely to make 
treatment effects depart from plausible values. The study used 
sufficient methods, such as multiple imputation, to handle 
missing data. 
• Unclear risk of bias: there was insufficient information to 
assess whether missing data in combination with the method 
used to handle missing data were likely to induce bias on the 
results. 
• High risk of bias: the results were likely to be biased due to 
missing data. 
Selective outcome reporting 
• Low risk of bias: the trial reported the following predefined 
outcomes: at least one of the outcomes related to the main reason 
for treatment of people with SBP, namely, all-cause mortality, 
resolution of SBP along with adverse events. If the original trial 
protocol was available, the outcomes should have been those 
called for in that protocol. If the trial protocol was obtained from 
a trial registry (e.g. ClinicalTrials.gov), the outcomes sought 
should have been those enumerated in the original protocol if 
the trial protocol was registered before or at the time that the 
trial was begun. If the trial protocol was registered after the trial 
was begun, those outcomes will not be considered to be reliable. 
• Unclear risk of bias: not all predefined, or clinically relevant 
and reasonably expected, outcomes were reported fully; or it was 
unclear whether data on these outcomes were recorded or not. 
• High risk of bias: one or more predefined or clinically 
relevant and reasonably expected outcomes were not reported, 
despite the fact that data on these outcomes should have been 
available and recorded. 
Other bias 
• Low risk of bias: the trial appeared to be free of other 
components that could put it at risk of bias (e.g. inappropriate 
control or dose or administration of control, baseline differences, 
early stopping). 
• Unclear risk of bias: the trial may or may not have been free 
of other components that could put it at risk of bias. 
• High risk of bias: there were other factors in the trial that 
could put it at risk of bias (e.g. baseline differences, early 
stopping). 
We considered a trial to be at low risk of bias if we assessed the trial 
to be at low risk of bias across all listed bias risk domains. Oth­
erwise, we considered trials to be at high risk of bias. At the out­
come level, we classified an outcome to be at low risk of bias if the 
allocation sequence generation, allocation concealment, blinding 
of participants, healthcare professionals, and outcome assessors, 
incomplete outcome data, and selective outcome reporting (at the 
outcome level) were at low risk of bias for objective and subjective 
outcomes (Savovi 2018). 
Measures of treatment effect 
Relative treatment effects 
For dichotomous variables (e.g. proportion of participants with 
serious adverse events or any adverse events), we calculated the 
odds ratio (OR) with 95% credible interval (CrI) (or Bayesian 
confidence interval) (Severini 1993). For continuous variables (e.g. 
length of hospital stay), we calculated the mean difference (MD) 
with 95% Crl. We planned to use standardised mean difference 
(SMD) values with 95% Crl for health-related quality of life if 
included trials used different scales. We planned to obtain the 
final scores whenever possible. For count outcomes (e.g. number 
of serious adverse events or number of any adverse events), we 
calculated the rate ratio with 95% Crl. This assumes that the events 
are independent of each other, i.e. if a person has had an event 
they are not at an increased risk of further outcomes, which is the 
assumption in Poisson likelihood. For time-to-event data (e.g. all­
cause mortality at maximal follow-up), we calculated hazard ratio 
(HR) with 95% Crl. 
Relative ranking 
We estimated the ranking probabilities with 95% CrI for all in­
terventions of being at each possible rank for each intervention. 
We obtained the surface under the cumulative ranking curve (SU­
CRA) (cumulative probability), rankogram, and relative rank­
ing table with CrI for the ranking probabilities (Salanti 2011; 
Chaimani 2013). 
Unit of analysis issues 
The unit of analysis was the participant undergoing treatment for 
SBP according to the intervention group to which the participant 
was randomly assigned. 
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Cluster-randomised clinical trials 
If we identified any cluster-randomised clinical trials, we planned 
to include cluster-randomised clinical trials, provided that the ef­
fect estimate adjusted for cluster correlation was available or if 
there was sufficient information available to calculate the design 
effect (which would allow us to take clustering into account). We 
also planned to assess additional domains of risk of bias for cluster­
randomised trials according to guidance in the Cochrane Hand­
book for Systematic Reviews of Interventions (Higgins 2011). 
Cross-over randomised clinical trials 
If we identified any cross-over randomised clinical trials, we 
planned to include only the outcomes after the period of first in­
tervention because the included treatments could have residual 
effects. 
Trials with multiple intervention groups 
We collected data for all trial intervention groups that met the 
inclusion criteria. The codes, we used for analysis, accounted for 
the correlation between the effect sizes from trials with more than 
two groups. 
Dealing with missing data 
We performed an intention-to-treat analysis whenever possible 
(Newell 1992); otherwise, we used the data available to us. When 
intention-to-treat analysis is not used and the data are not missing 
at random (for example, treatment was withdrawn due to adverse 
events or duration of treatment was shortened because of lack of 
response and such participants were excluded from analysis), this 
can lead to biased results; therefore, we conducted best-worst case 
scenario analysis (assuming a good outcome in the intervention 
group and bad outcome in the control group) and worst-best case 
scenario analysis (assuming a bad outcome in the intervention 
group and good outcome in the control group) as sensitivity anal­
yses whenever possible for binary and time-to-event outcomes, 
where binomial likelihood was used. 
For continuous outcomes, we planned to impute the standard 
deviation from P values, according to guidance in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins 2011). 
If the data were likely to be normally distributed, we planned to 
use the median for meta-analysis when the mean was not available; 
otherwise, we planned to simply provide a median and interquar­
tile range of the difference in medians. If it was not possible to 
calculate the standard deviation from the P value or the confidence 
intervals, we planned to impute the standard deviation using the 
largest standard deviation in other trials for that outcome. This 
form of imputation can decrease the weight of the study for cal­
culation of mean differences and may bias the effect estimate to 
no effect for calculation of standardised mean differences (Higgins 
2011). 
Assessment of heterogeneity 
We assessed clinical and methodological heterogeneity by carefully 
examining the characteristics and design of included trials. We also 
planned to assess the presence of clinical heterogeneity by compar­
ing effect estimates (please see Subgroup analysis and investigation 
of heterogeneity) in trial reports of different drug dosages, pres­
ence of other features of decompensation (hepatorenal syndrome, 
hepatic encephalopathy, or variceal bleeding), different aetiologies 
for cirrhosis (for example, alcohol-related liver disease, viral liver 
diseases, autoimmune liver disease), and based on the cointerven­
tions (for example, both groups receive albumin). Different study 
designs and risk of bias can contribute to methodological hetero­
geneity. 
We assessed statistical heterogeneity by comparing the results of 
the fixed-effect model meta-analysis and the random-effects model 
meta-analysis, between-study variance (Tau2, and comparing this 
with values reported in the study of the distribution of between­
study heterogeneity) (Turner 2012), and by calculating I2 (Jackson 
2014), using Stata/SE 15.1 (if applicable). If we identified sub­
stantial clinical, methodological, or statistical heterogeneity, we 
planned to explore and address the heterogeneity in subgroup anal­
ysis (see ’Subgroup analysis and investigation of heterogeneity’). 
Assessment of transitivity across treatment 
comparisons 
We assessed the transitivity assumption by comparing the distri­
bution of the potential effect modifiers (clinical: presence of other 
features of decompensation, i.e. hepatorenal syndrome, hepatic 
encephalopathy, or variceal bleeding; methodological: risk of bias, 
year of randomisation, duration of follow-up) across the different 
pairwise comparisons. 
Assessment of reporting biases 
For the network meta-analysis, we planned to perform a compari­
son-adjusted funnel plot. However, to interpret a comparison-ad­
justed funnel plot, it is necessary to rank the studies in a meaning­
ful way as asymmetry may be due to small sample sizes in newer 
studies (comparing newer treatments with older treatments) or 
higher risk of bias in older studies (comparing older treatments 
with placebo) (Chaimani 2012). As there was no meaningful way 
in which to rank these studies (i.e. there was no specific change 
in the risk of bias in the studies, sample size, or the control group 
used over time), we judged the reporting bias by the completeness 
of the search (Chaimani 2012). 
Data synthesis 
Methods for indirect and mixed comparisons 
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We conducted network meta-analyses to compare multiple in­
terventions simultaneously for each of the primary and sec­
ondary outcomes. Network meta-analysis combines direct evi­
dence within trials and indirect evidence across trials (Mills 2012). 
We obtained a network plot to ensure that the trials were connected 
by interventions using Stata/SE 15.1 (Chaimani 2013). We ex­
cluded any trials that were not connected to the network from the 
network meta-analysis, and we reported only the direct pairwise 
meta-analysis for such comparisons. We summarised the popula­
tion and methodological characteristics of the trials included in the 
network meta-analysis in a table based on pairwise comparisons. 
We conducted a Bayesian network meta-analysis using the Markov 
chain Monte Carlo method in OpenBUGS 3.2.3, according to 
guidance from the National Institute for Health and Care Ex­
cellence (NICE) Decision Support Unit (DSU) documents (Dias 
2016). We modelled the treatment contrast (i.e. log odds ratio for 
binary outcomes, mean difference or standardised mean difference 
for continuous outcomes, log rate ratio for count outcomes, and 
log hazard ratio for time-to-event outcomes) for any two interven­
tions (’functional parameters’) as a function of comparisons be­
tween each individual intervention and the reference group (’basic 
parameters’), using appropriate likelihood functions and links (Lu 
2006). We used binomial likelihood and logit link for binary out­
comes, Poisson likelihood and log link for count outcomes, bino­
mial likelihood and complementary log-log link (a semiparametric 
model which excludes censored individuals from the denominator 
of ’at risk’ individuals at the point when they are censored), and 
normal likelihood and identity link for continuous outcomes. We 
used ’ceftriaxone’ as the reference group as this was the commonest 
intervention in the trials included in this review. We used a fixed-
effect model and a random-effects model for the network meta­
analysis. We planned to report both models for comparison with 
the reference group in a forest plot, when applicable. For each 
pairwise comparison in a table, we reported the fixed-effect model 
if the two models reported similar results; otherwise, we planned 
to report the more conservative model. 
We used a hierarchical Bayesian model using three different sets of 
initial values to start the simulation-based parameter estimation, 
employing codes provided by NICE DSU (Dias 2016). We used 
a normal distribution with large variance (10,000) for treatment 
effect priors (vague or flat priors) centred at no effect. For the ran­
dom-effects model, we used a prior distributed uniformly (lim­
its: 0 to 5) for the between-trial standard deviation and assumed 
this variability would be the same across treatment comparisons 
(Dias 2016). We used a ’burn-in’ of 30,000 iterations, checked for 
convergence (of effect estimates and between-study heterogeneity) 
visually (i.e. checked whether the values in different chains mix 
very well by visualisation), and ran the models for another 10,000 
simulations to obtain effect estimates. If we did not obtain con­
vergence, we increased the number of simulations for the ’burn­
in’ and used the ’thin’ and ’over relax’ functions to decrease the 
to use alternate initial values and priors employing methods sug­
gested by van Valkenhoef 2012. We estimated the probability that 
each intervention ranks at each of the possible positions using the 
NICE DSU codes (Dias 2016). 
Assessment of inconsistency 
We assessed inconsistency (statistical evidence of the violation of 
transitivity assumption) by fitting both an inconsistency model 
and a consistency model. We used inconsistency models employed 
in the NICE DSU manual, as we used a common between-study 
standard deviation (Dias 2014). In addition, we planned to use 
design-by-treatment full interaction model and inconsistency fac­
tor plots to assess inconsistency when applicable (Higgins 2012; 
Chaimani 2013). We planned to report inconsistency factor plots 
when possible using Stata/SE 15.1. In the presence of inconsis­
tency, we planned to assess whether the inconsistency was due 
to clinical or methodological heterogeneity by performing sepa­
rate analyses for each of the different subgroups mentioned in the 
’Subgroup analysis and investigation of heterogeneity’ section. 
If there was evidence of inconsistency, we planned to identify areas 
in the network where substantial inconsistency might be present 
in terms of clinical and methodological diversities between trials 
and, when appropriate, limit network meta-analysis to a more 
compatible subset of trials. 
Direct comparison 
We performed the direct comparisons using the same codes and 
the same technical details. 
Subgroup analysis and investigation of heterogeneity 
We planned to assess the differences in the effect estimates between 
the following subgroups and investigate heterogeneity and incon­
sistency using meta-regression with the help of the codes provided 
in the NICE DSU guidance (Dias 2012a), if we included a suffi­
cient number of trials (when there were at least two trials in at least 
two of the subgroups) and when the interaction term could be 
calculated. We planned to use the following trial-level covariates 
for meta-regression. 
• Trials at low risk of bias compared to trials at high risk of 
bias 
• The presence of other features of decompensation 
(hepatorenal syndrome, hepatic encephalopathy, or variceal 
bleeding) 
• The aetiology for cirrhosis (for example, alcohol-related 
liver disease, viral liver diseases, autoimmune liver disease) 
• Community acquired or nosocomial SBP 
• The interval between the diagnosis of SBP and the start of 
treatment 
• Different types of cointerventions (for example, both 
autocorrelation. If we still did not obtain convergence, we planned 
groups receive albumin as the cointervention) 
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• The period of follow-up (short-term: up to 3 months; 
medium-term: more than 3 months to 5 years; long-term: more 
than 5 years) 
• The definition used by authors for serious adverse events 
and any adverse events compared to other definitions 
(ICH-GCP 1997) 
We planned to calculate a single common interaction term (which 
assumes that each relative treatment effect versus a common com­
parator treatment is impacted in the same way by the covariate in 
question) when applicable (Dias 2012a). If the 95% Crl of the in­
teraction term did not overlap zero, we would have considered this 
statistically significant heterogeneity or inconsistency (depending 
upon the factor being used as covariate). 
Sensitivity analysis 
If there were post-randomisation dropouts, we reanalysed the re­
sults using the best-worst case scenario and worst-best case sce­
nario analyses as sensitivity analyses whenever possible. We also 
planned to perform a sensitivity analysis excluding the trials in 
which mean or standard deviation, or both were imputed, and 
use the median standard deviation in the trials to impute missing 
standard deviations. 
Presentation of results 
We followed the PRISMA-NMA statement while reporting the 
results (Hutton 2015). We presented the effect estimates with 95% 
CrI for each pairwise comparison calculated from the direct com­
parisons and the network meta-analysis. We originally planned 
to present the cumulative probability of the treatment ranks (i.e. 
the probability that the intervention is within the top two, the 
probability that the intervention is within the top three, etc.) in 
graphs (SUCRA) (Salanti 2011). We plotted the probability that 
each intervention was best, second best, third best, etc. for each 
of the different outcomes (rankograms), which are generally con­
sidered more informative (Salanti 2011; Dias 2012b), but we did 
not present these because of the sparse data which can lead to mis­
interpretation of results due to large uncertainty in the rankings 
(the CrI was 0 to 1 for all the ranks). We uploaded all the raw data 
and the codes used for analysis in The European Organization 
for Nuclear Research open source database (Zenodo) (the link is 
doi.org/10.5281/zenodo.3256132). 
Grading of evidence 
We presented ’Summary of findings’ tables for all the pri­
mary and secondary outcomes (see Primary outcomes; Secondary 
outcomes). We followed the approach suggested by Yepes-Nunez 
and colleagues (Yepes-Nunez 2019). First, we calculated the di­
rect and indirect effect estimates (when possible) and 95% Crl 
using the node-splitting approach (Dias 2010), that is, calculating 
the direct estimate for each comparison by including only trials 
in which there was direct comparison of interventions and the 
indirect estimate for each comparison by excluding the trials in 
which there was direct comparison of interventions (and ensuring 
a connected network). Next, we rated the quality of direct and 
indirect effect estimates using GRADE methodology which takes 
into account the risk of bias, inconsistency (heterogeneity), direct­
ness of evidence (including incoherence, the term used in GRADE 
methodology for inconsistency in network meta-analysis), impre­
cision, and publication bias (Guyatt 2011). We then presented 
the relative and absolute estimates of the meta-analysis with the 
best certainty of evidence (Yepes-Nunez 2019). We also presented 
the ’Summary of findings’ tables in a second format presenting 
all the outcomes for selected interventions (Yepes-Nunez 2019): 
we selected the three interventions (cetriaxone, cefotaxime, and 
ciprofloxacin) which were compared in most trials. 
Recommendations for future research 
We provided recommendations for future research regarding the 
population, intervention, control, outcomes, period of follow-up, 
and study design, based on the uncertainties that we identified 
from the existing research. 
R E S U L T S 
Description of studies 
Results of the search 
We identified 1322 references through electronic searches of CEN­
TRAL (n = 183), MEDLINE Ovid (n = 501), Embase Ovid (n 
= 238), Science Citation Index Expanded (n = 316), ClinicalTri­
als.gov (n = 35) and WHO Trials register (n = 49). After remov­
ing duplicate references, there were 1050 references. We excluded 
1022 clearly irrelevant references through reading titles and ab­
stracts. We did not identify any additional eligible trial by refer­
ence searching or by searching the European Medicines Agency 
(EMA) or Food and Drug Administration (FDA). We retrieved a 
total of 28 full-text references for further assessment in detail. We 
excluded 11 references for the reasons stated in the Characteristics 
of excluded studies. Thus, we included a total of 12 trials described 
in 17 references (Characteristics of included studies). The refer­
ence flow is shown in Figure 2. 
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Figure 2. Study flow diagram. 








We included 12 trials (Gomez-Jimenez 1993; Navasa 1996; 
Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 
2006; Ahmed Ather Ch 2014; Abd-Elsalam 2016; Jindal 2016; 
Piano 2016; Yim 2017). A total of 1272 participants were ran­
domised to different interventions. The number of participants 
ranged from 20 to 261. A total of 893 participants from 10 tri­
als provided data for one or more outcomes (Gomez-Jimenez 
1993; Navasa 1996; Figueiredo 1997; Rastegar 1998; Tuncer 
2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 2014; Jindal 
2016; Piano 2016). The mean or median age in the trials ranged 
from 42 to 60 years in the trials that reported this information 
(Gomez-Jimenez 1993; Navasa 1996; Figueiredo 1997; Rastegar 
1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 
2014; Jindal 2016; Piano 2016). The proportion of females ranged 
from 18.3% to 42.1% in the trials that reported this information 
(Gomez-Jimenez 1993; Navasa 1996; Figueiredo 1997; Rastegar 
1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 
2014; Jindal 2016; Piano 2016). The most common organism 
isolated was Eschericia coli (E coli) (18.6% to 56.7%) in the tri­
als that reported the isolated micro-organisms (Gomez-Jimenez 
1993; Navasa 1996; Chen 2005; Angeli 2006). The next most 
common was the Klebsiella species (5.0% to 5.7%) and Streptococ­
cus pneumoniae (S pneumoniae) (1.7% to 9.8%) (Gomez-Jimenez 
1993; Navasa 1996); the remaining organisms were less frequent. 
All trials had short-term follow-up (Gomez-Jimenez 1993; Navasa 
1996; Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; 
Angeli 2006; Ahmed Ather Ch 2014; Abd-Elsalam 2016; Jindal 
2016; Piano 2016; Yim 2017), ranging from one week to three 
months. 
A total of 13 interventions were compared in the trials. Ceftriax­
one, cefotaxime, and ciprofloxacin were the commonest antibiotics 
compared in the trials. The important characteristics, antibiotics 
compared, potential effect modifiers, and follow-up in each trial 
are reported in Table 1. None of the trials compared antibiotics 
with no treatment or placebo. Overall, no systematic differences 
between any of the comparisons seemed to exist. 
None of the trials reported the proportion of people with other 
features of decompensation, such as hepatorenal syndrome and 
active variceal bleeding. The proportion of participants with alco­
hol-related cirrhosis ranged between 13.5% to 64.5% in the tri­
als that reported this information (Gomez-Jimenez 1993; Navasa 
1996; Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). The 
proportion of participants with viral-related cirrhosis ranged be­
tween 20.6% to 81.1% in the trials that reported this information 
(Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). None of the 
trials reported the proportion of people with autoimmune disease­
related cirrhosis. The proportion of participants with other causes 
for cirrhosis ranged between 5.4% to 56.9% in the trials that 
reported this information (Gomez-Jimenez 1993; Navasa 1996; 
Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). None of the 
trials reported the proportion of people treated for ascites, in ad­
dition to antibiotics (for example, albumin or diuretics). 
Funding: the source of funding for two trials was industrial organ­
isations who would benefit from the results of the study (Navasa 
1996; Piano 2016); the source of funding for the remaining 10 tri­
als was unclear (Gomez-Jimenez 1993; Figueiredo 1997; Rastegar 
1998; Tuncer 2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 
2014; Abd-Elsalam 2016; Jindal 2016; Yim 2017). 
Excluded studies 
The reasons for exclusion are provided in the ’Characteristics of 
excluded studies’ tables. 
Risk of bias in included studies 
The risk of bias is summarised in Figure 3, Figure 4, and in Table 
2. As none of the trials were at low risk of bias in all domains, we 
considered all trials to be at high risk of bias. 
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies. 
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Figure 4. Risk of bias summary: review authors’ judgements about each risk of bias item for each included 
study. 








Four trials were at low risk of sequence generation bias (Navasa 
1996; Angeli 2006; Ahmed Ather Ch 2014; Piano 2016); the 
remaining eight trials, which did not provide sufficient details, 
were at unclear risk of sequence generation bias (Gomez-Jimenez 
1993; Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; 
Abd-Elsalam 2016; Jindal 2016; Yim 2017). 
Three trials were at low risk of allocation concealment bias (Navasa 
1996; Angeli 2006; Piano 2016); the remaining nine trials, which 
did not provide sufficient details, were at unclear risk of alloca­
tion concealment bias (Gomez-Jimenez 1993; Figueiredo 1997; 
Rastegar 1998; Tuncer 2003; Chen 2005; Ahmed Ather Ch 2014; 
Abd-Elsalam 2016; Jindal 2016; Yim 2017). 
Blinding 
None of the trials were at low risk of blinding of patients and 
healthcare providers’ bias; 10 trials were at unclear risk of blinding 
of patients and healthcare providers’ bias (Navasa 1996; Figueiredo 
1997; Rastegar 1998; Tuncer 2003; Chen 2005; Angeli 2006; 
Ahmed Ather Ch 2014; Abd-Elsalam 2016; Piano 2016; Yim 
2017); the remaining two trials were at high risk of blinding of 
patients and healthcare providers’ bias (Gomez-Jimenez 1993; 
Jindal 2016). 
None of the trials were at low risk of blinding of outcome assessors’ 
bias; 10 trials were at unclear risk of blinding of outcome assessors’ 
bias (Navasa 1996; Figueiredo 1997; Rastegar 1998; Tuncer 2003; 
Chen 2005; Angeli 2006; Ahmed Ather Ch 2014; Abd-Elsalam 
2016; Piano 2016; Yim 2017); the remaining two trials were at 
high risk of blinding of outcome assessors’ bias (Gomez-Jimenez 
1993; Jindal 2016). 
Incomplete outcome data 
Four trials were at low risk of missing outcome bias (Figueiredo 
1997; Tuncer 2003; Angeli 2006; Jindal 2016); seven trials were 
at unclear risk of missing outcome bias (Gomez-Jimenez 1993; 
Navasa 1996; Rastegar 1998; Ahmed AtherCh 2014; Abd-Elsalam 
2016; Piano 2016; Yim 2017), because they either did not state 
the number of post-randomisation dropouts or we could not as­
sess whether the post-randomisation dropouts were related to the 
intervention and outcome; the remaining one trial was at high risk 
of missing outcome bias, because the post-randomisation drop­
outs were likely to be related to the outcome (Chen 2005). 
Selective reporting 
Six trials were at low risk of selective outcome reporting bias 
(Gomez-Jimenez 1993; Navasa 1996; Tuncer 2003; Angeli 2006; 
Jindal 2016; Piano 2016): although a protocol published prior to 
recruitment was not available for these trials, these trials reported 
all-cause mortality or resolution of SBP along with adverse events; 
the remaining six trials were at high risk of selective outcome re­
porting bias (Figueiredo 1997; Rastegar 1998; Chen 2005; Ahmed 
Ather Ch 2014; Abd-Elsalam 2016; Yim 2017): a protocol pub­
lished prior to recruitment was not available for these trials, and 
these trials did not report reasonably expected clinical outcomes 
which would have been measured in a trial of this nature. 
Other potential sources of bias 
There were no other biases in the trials. 
Effects of interventions 
See: Summary of findings for the main comparison; Summary 
of findings 2 
The network plot for all outcomes for which network meta-analy­
sis was performed is shown in Figure 1. If a network meta-analysis 
was not performed, the reason for not performing the network 
meta-analysis is reported under the outcome. Only one trial was 
included for each comparison in all outcomes other than resolu­
tion of spontaneous bacterial peritonitis (SBP). Even for resolution 
of SBP, where one of the comparisons had two trials, the between­
study standard deviation was the same as the mean of the prior dis­
tribution: the 95% credible intervals (CrIs) of the random-effects 
model were not representative. Therefore, we used the fixed-effect 
model for all the network meta-analyses and did not present the 
forest plots comparing the fixed-effect and random-effects mod­
els. In addition, the deviance information criteria statistics showed 
that model fit was not improved with the random-effects model 
(Table 3), and the random-effects model did not alter the interpre­
tation on the effectiveness of treatments. These findings support 
the use of the fixed-effect model. 
There was no evidence of inconsistency, as indicated by deviance 
information criteria. As a consequence of the sparse data (only 1 
trial was included for each comparison for most outcomes), we did 
not consider the results from the design-by-treatment interaction 
model to assess inconsistency. We were unable to obtain inconsis­
tency factor plots in Stata/SE 15.1. This was either because there 
was only one closed loop resulting from a single three-arm trial or 
because heterogeneity could not be calculated due to the presence 
of a single trial for the comparison. 
The 95% CrI of the probability ranks were wide and included 0 
and 1 in all the comparisons for all the outcomes. This was proba­
bly because of the sparse data from small trials. Therefore, we did 
not present the ranking probabilities (in a table), rankograms, and 
SUCRA plots as we considered that presenting this information 
would be misleading due to large uncertainty in the rankings. 
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Certainty of evidence was very low for all the comparisons. This 
was because all the trials were at unclear or high risk of bias for 
two or more risk of bias domains at the outcome level (down­
graded 1 level), the sample size was small (downgraded 1 level), 
and the wide CrIs overlapping significant clinical effect and no 
effect (downgraded 1 level). There was no evidence of indirect­
ness or publication bias. We could not assess inconsistency in the 
GRADE context (i.e. heterogeneity) as there was only one trial for 
each comparison for most outcomes. 
All-cause mortality 
Nine trials (653 participants) reported all-cause mortality (Gomez-
Jimenez 1993; Navasa 1996; Figueiredo 1997; Rastegar 1998; 
Tuncer 2003; Chen 2005; Angeli 2006; Jindal 2016; Piano 2016). 
A total of 13 interventions were compared with each other. There 
were nine interventions connected to the network (Figure 1), and 
four unconnected interventions. Only one trial was included in 
each pairwise comparison. There were no significant differences in 
the all-cause mortality between any of the interventions included 
in the network meta-analysis (Table 4). There were also no signif­
icant differences in the all-cause mortality between the following 
comparisons which could not be included in the network meta­
analysis because they were not connected. 
• Pefloxacin versus ampicillin plus gentamycin: HR 0.80 
(95% CrI 0.02 to 30.66). 
• Imipenem versus cefepime: HR 0.98 (95% CrI 0.60 to 
1.57). 
Health-related quality of life 
None of the trials reported health-related quality of life. 
Serious adverse events 
One trial (31 participants) reported the proportion of participants 
with serious adverse events (Piano 2016). It was not clear whether 
the authors used the ICH-GCP definition of serious adverse events 
(ICH-GCP 1997). There was no significant difference in the pro­
portion of people with serious adverse events between meropenem 
plus daptomycin versus ceftazidime: odds ratio (OR) 1.51 (95% 
credible interval (CrI) 0.35 to 6.71). None of the trials reported 
the number of serious adverse events per participant. 
Any adverse event 
Five trials (297 participants) reported the proportion of partic­
ipants with any adverse event (Gomez-Jimenez 1993; Tuncer 
2003; Chen 2005; Angeli 2006; Piano 2016). It was not clear 
whether the authors used the ICH-GCP definition of adverse 
events (ICH-GCP 1997). A total of seven interventions were com-
pared with each other. All the interventions were connected (Figure 
1). Only one trial compared each pairwise comparison. The fixed­
effect model was used. There were no significant differences in the 
proportion of people who developed any adverse event between 
any of the interventions (Table 4). 
Two trials (291 participants) reported the number of any adverse 
events (Angeli 2006; Jindal 2016). It was not clear whether the au­
thors used the ICH-GCP definition of adverse events (ICH-GCP 
1997). The two trials compared two different pairs of inter­
ventions. Therefore, network meta-analysis was not appropriate. 
There were no significant differences in the number of adverse 
events per participant in the following comparisons. 
• Ceftazdime versus ciprofloxacin: rate ratio 1.39 (95% CrI 
0.79 to 2.48). 
• Imipenem versus cefepime: rate ratio 1.00 (95% CrI 0.83 
to 1.20). 
Liver transplantation 
One trial (31 participants) reported the proportion of participants 
requiring liver transplantation (Piano 2016). There was no signif­
icant difference in the proportion of people who underwent liver 
transplantation between meropenem plus daptomycin versus cef­
tazidime: hazard ratio (HR) 1.77 (95% CrI 0.26 to 15.21). 
Resolution of SBP 
None of the trials reported resolution of SBP, defined as symp­
tomatic recovery from SBP. Nine trials (873 participants) re­
ported recovery from SBP, as per definitions used for SBP 
(Gomez-Jimenez 1993; Navasa 1996; Figueiredo 1997; Tuncer 
2003; Chen 2005; Angeli 2006; Ahmed Ather Ch 2014; Jindal 
2016; Piano 2016). We compared a total of 11 interventions with 
each other. There were eight connected interventions (Figure 1), 
and 3 unconnected interventions. Of these, we excluded one com­
parison because both interventions in the comparison were uncon­
nected. We excluded one intervention as it was connected to the 
network solely by one trial in which all participants had resolution 
of SBP. We included only one trial for each pairwise comparison, 
except for one pairwise comparison. There were no significant dif­
ferences in the proportion of people in whom resolution of SBP 
could be achieved (Table 4). 
There was no significant difference in the resolution of SBP be­
tween imipenem versus cefepime: HR 0.72 (95% CrI 0.45 to 
1.12). We could not obtain convergence for the other comparison 
involving cefonicid versus ceftriaxone, in which all 30 participants 
in the ceftriaxone group had resolution of SBP and 28/30 (93.3%) 
of the cefonicid group had resolution of SBP. 
Other features of decompensation 
Six trials (535 participants) reported other features of decompensa­
tion (Navasa 1996; Tuncer 2003; Chen 2005; Angeli 2006; Jindal 
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2016; Piano 2016). None of the trials reported the number of peo­
ple who developed decompensation; only the number of decom­
pensation events in each group was reported. A total of nine inter­
ventions were compared with each other. There were seven con­
nected interventions (Figure 1), and two unconnected interven­
tions. Only one trial was included for each pairwise comparison. 
There were no significant differences in the number of other de­
compensation events between any of the interventions included in 
the network meta-analysis (Table 4). There was also no significant 
difference in the number of other decompensation events between 
the unconnected interventions (imipenem versus cefepime): rate 
ratio 0.97 (95% CrI 0.75 to 1.25). 
Length of hospital stay 
Two trials (160 participants) reported length of hospital stay 
(Navasa 1996; Chen 2005). A total of three interventions were 
compared with each other. All the interventions were connected 
(Figure 1). Only one trial was included in each pairwise compari­
son. There were no significant differences in the length of hospital 
stay between any of the interventions (Table 4). 
Number of work days lost 
None of the trials reported this outcome. 
Treatment costs 
None of the trials reported total treatment costs. Two trials 
(91 participants) reported antibiotic costs for the regimen used 
(Figueiredo 1997; Tuncer 2003). The standard deviation of the 
costs were not reported and could not be calculated from other 
data available in either trial. 
In one trial, oral cefixime was compared with intravenous ceftriax­
one (Figueiredo 1997). The non-inflated costs of antibiotic treat­
ment were BRL 62 for the oral cefixime group compared to BRL 
2160 for the intravenous ceftriaxone group (Figueiredo 1997). In 
the second trial, oral ciprofloxacin was compared with intravenous 
cefotaxime and intravenous ceftriaxone. The non-inflated costs of 
antibiotic treatment were USD 6.61 for oral ciprofloxacin, USD 
127 for intravenous cefotaxime, and USD 118 for intravenous 
ceftriaxone groups (Tuncer 2003). 
Subgroup analysis 
We did not perform any of the planned subgroup analysis because 
of sparse data in the trials, short follow-up in all trials, and the 
unclear or high risk of bias for each of the outcomes in all trials. 
Sensitivity analysis 
The scenario analysis we performed for post-randomisation drop­
outs for binary outcomes and time-to-event outcomes (where bi­
nomial likelihood was used). None of these revealed any alterations 
in the results. We did not impute the standard deviation for any 
continuous outcome. 
Assessment of reporting biases 
We were unable to perform the comparison-adjusted funnel plot 
because there was no meaningful way in which to rank the studies 
(i.e. there was no specific change in the risk of bias in the studies, 
sample size, or the control group used over time). 













































































































































A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation] 
Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis 
Patient or population: people with cirrhosis and spontaneous bacterial peritonit is 
Settings: secondary or tert iary care 
Intervention: various intervent ions 
Comparison: cef triaxone 
Follow-up period: 1 week to 3 months 
Network geometry plots: Figure 1 
Outcomes Cefotaxime Ciprofloxacin 
All- cause mortality 
Ceftriaxone 
263 per 1000 
(26.3%) 
HR 0.56 
(0.11 to 2.28) 
Network estimate 
117 fewer per 1000 
(235 f ewer to 336 more) 
HR 0.65 
(0.12 to 2.72) 
Network estimate 
92 fewer per 1000 
(232 f ewer to 454 more) 
Very low1,2,3 Very low1,2,3 
­ Rank: ­ Rank: ­
Based on 37 part icipants (1 RCT) Based on 35 part icipants (1 RCT) 
Adverse events (proportion of participants) 
Ceftriaxone 
67 per 1000 
(6.7%) 
OR 0.64 
(0.15 to 2.62) 
Network estimate 
23 fewer per 1000 
(56 f ewer to 91 more) 
OR 1.02 
(0.24 to 4.16) 
Network estimate 
1 more per 1000 
(50 f ewer to 162 more) 
Very low1,2,3 Very low1,2,3 
­ Rank: ­ Rank: ­











































































































































Spontaneous bacterial peritonitis (as per definition used for spontaneous bacterial peritonitis) 
Cef triaxone 
733 per 1000 
(73.3%) 
HR 0.90 
(0.42 to 1.86) 
Network estimate 
73 fewer per 1000 
(425 f ewer to 267 more) 
HR 0.93 
(0.69 to 1.25) 
Network estimate 
54 fewer per 1000 
(230 f ewer to 183 more) 
Very low1,2,3 Very low1,2,3 
Rank: ­ Rank: ­ Rank: ­
Based on 37 part icipants (1 RCT) Based on 275 part icipants (2 RCT) 
Other features of decompensation (per participant) 
Ceftriaxone 
368 per 1000 
(36.8 per 100 part icipants) 
Rate ratio 1.22 
(0.43 to 3.53) 
Network est imate 
80 more per 1000 
(209 f ewer to 933 more) 
Rate ratio 1.01 
(0.32 to 3.16) 
Network est imate 
4 more per 1000 
(249 f ewer to 795 more) 
Very low1,2,3 Very low1,2,3 
Rank: ­ Rank: ­
Based on 37 part icipants (1 RCT) Based on 35 part icipants (1 RCT) 
Rank: ­
*Ranking is not provided as the median rank was not 1 f or at least one of the ranking posit ions f or each intervent ion f or the outcome 
CrI: credible interval; HR: hazard rat io; OR: odds rat io; RCT : randomised clinical t rial 
GRADE Working Group grades of evidence 
High certainty: we are very conf ident that the t rue ef fect l ies close to that of the est imate of the ef fect. 
Moderate certainty: we are moderately conf ident in the ef fect est imate; the t rue ef fect is l ikely to be close to the est imate of the ef fect, but there is a possibility that it is 
substant ially dif ferent. 
Low certainty: our conf idence in the ef fect est imate is l im ited; the t rue ef fect may be substant ially dif ferent f rom the est imate of the ef fect. 
Very low certainty: we have very l it t le conf idence in the ef fect est imate; the t rue ef fect is l ikely to be substant ially dif ferent f rom the est imate of ef fect 
a The t rial(s) included in the analysis was/ were at high risk of bias (downgraded one level).
 
bThe sample size was small (downgraded one level).
 
cThe credible intervals were wide (includes clinical benef it and harms) (downgraded one level).
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D I S C U S S I O N Certainty of the evidence 
Summary of main results 
We performed a systematic review and network meta-analysis of 
all the antibiotic treatments for spontaneous bacterial peritonitis 
(SBP) in people with decompensated liver cirrhosis. We included 
a total of 12 trials, with a total of 1272 participants in this review. 
In the four trials that reported the isolated organisms, the most 
common organism isolated was Eschericia coli (E coli) (18.6% to 
56.7%) (Gomez-Jimenez 1993; Navasa 1996; Chen 2005; Angeli 
2006). We compared a total of 13 interventions in these trials. A 
total of 10 trials, including 893 participants were included for one 
or more outcomes of this review (Gomez-Jimenez 1993; Navasa 
1996; Figueiredo 1997; Rastegar 1998; Tuncer 2003; Chen 2005; 
Angeli 2006; Ahmed Ather Ch 2014; Jindal 2016; Piano 2016). 
Only one outcome, resolution of SBP, featured more than one trial 
for the same comparison. 
Approximately 75% of participants with SBP had resolution of 
SBP, and 25% of participants died from SBP. Overall, there was 
no evidence of differences for any of the primary or secondary 
outcomes of this review. However, it should be noted that the 
data were sparse and most of the comparisons involved a single 
trial. Therefore, clinically important differences in the outcomes 
between the interventions are possible. 
Future trials can and should be powered on short-term all-cause 
mortality. Based on the probability ranks, it is not clear which in­
terventions should be compared in future trials. Intravenous cef­
triaxone and cefotaxime were the commonest interventions used 
in the trials. The sample size required in such trials based on a 
control group proportion of 25% (weighted median control group 
proportion in ceftriaxone in the trials), a relative risk reduction of 
all-cause mortality of 20% in the experimental group, type I error 
of 5%, and type II error of 20% is 2188 participants. In such a 
trial, health-related quality of life, and adverse events (due to any 
cause: disease-related, treatment-related, or comorbidity-related) 
should be assessed as outcomes. A short period of follow-up of 90 
days may be sufficient to determine the effectiveness of an inter­
vention. 
Overall completeness and applicability of 
evidence 
The trials included a wide variety of patients with SBP. There did 
not seem to be any restriction based on the aetiology or the pres­
ence of other features of decompensation in the trials that provided 
this information. Therefore, the results of the study are applicable 
in all people with cirrhosis and SBP. We excluded trials in which 
participants had undergone liver transplantation. Therefore, the 
findings of this review are not applicable in people with liver de­
compensation after liver transplantation. 
The overall certainty of evidence was very low. One of the main 
reasons for the very low-certainty evidence was the unclear or high 
risk of bias in many of the trials. It is possible to perform trials at 
low risk of bias in the field. To perform a trial at low risk of bias, 
randomisation can be performed using standard methods, for ex­
ample, web-based central randomisation; blinding can be achieved 
by using a double placebo design (i.e. a placebo for intervention 
and a placebo for control); an intention-to-treat analysis can be 
performed; and a protocol can be published prior to recruitment. 
None of these have any major ethical considerations; therefore, a 
low risk of bias trial is very much feasible. 
Another major reason for very low-certainty evidence is impreci­
sion: the trials had small sample sizes and the credible intervals 
(CrIs) overlapped clinically significant benefits and clinically sig­
nificant harms for all comparisons. Therefore, future trials should 
be adequately powered with sample sizes, as described in the pre­
vious section. 
Heterogeneity could not be measured because of the presence of 
a single trial for most comparisons. We used clinical outcomes; 
therefore, there is no issue of indirectness due to outcomes. The 
direct comparisons and network meta-analysis results did not re­
sult in altered conclusions and the indirect evidence was applicable 
only in very few comparisons because of the nature of the network. 
In the comparisons for which indirect evidence was available, the 
effect estimates were similar to that of direct comparisons. There 
was no evidence that the patient selection or methodological dif­
ferences were systematically different across comparisons (i.e. there 
was no concern regarding the transitivity assumption). Therefore, 
there is no concern about indirectness of evidence. There was no 
meaningful way to rank these studies (i.e. there was no specific 
change in the risk of bias in the studies, sample size, or the control 
group used over time); we have completed a thorough search for 
studies on effectiveness. We found no evidence of publication bias. 
Potential biases in the review process 
We selected a range of databases to search without using any lan­
guage restrictions and conducted the network meta-analysis ac­
cording to NICE DSU guidance (Dias 2016). In addition, we have 
analysed data using the fixed-effect and random-effects model, al­
though we used the fixed-effect model for all the outcomes for 
the reasons described above. These are the strengths of the review 
process. 
We have excluded studies that compared variations in duration 
or dose in the different interventions. Hence, this review does 
not provide information on whether one variation is better than 
another. Another major limitation of this review was the paucity 
of data. Few trials were included for each comparison; in many 
comparisons, only one trial was included. This makes it difficult to 
assess whether the effect estimates are reproducible. This paucity 
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of data decreases the confidence in the results. 
All of the network meta-analyses included only sparse data from 
trials at high risk of bias. We were able to compare the direct and 
indirect estimates for very few comparisons. However, the poten­
tial effect modifiers in the trials that reported them were broadly 
similar across comparisons. The results of direct comparisons and 
indirect comparisons were also similar, when applicable. However, 
one cannot rule out violation of the transitivity assumption be­
cause of the sparse data; potential differences in the cointerven­
tions, and potential differences in the definitions used by trial au­
thors for adverse events and serious adverse events. 
We included only randomised clinical trials which are known to 
focus mostly on benefits and do not collect and report harms in 
a detailed manner. Therefore, it is possible that we missed a large 
number of non-randomised studies addressing the reporting of 
harms. A significant effort is required to identify the non-ran­
domised studies and assess the risk of bias in those studies. Since 
it is possible to conduct future studies powered on mortality, a 
systematic review on adverse events appears to be unnecessary in a 
superiority trial (as a treatment that reduces short-term mortality 
will be used even if it increases the adverse events). 
Agreements and disagreements with other 
studies or reviews 
This is the first network meta-analysis on the topic. The 
only systematic review on this topic compared third-generation 
cephalosporins with other empirical broad-spectrum antibiotics 
in patients with nosocomial SBP (Fiore 2018). This study in­
cluded eight non-randomised studies and concluded that there 
was higher prevalence of antibiotic resistance to third-generation 
cephalosporins than empirical broad-spectrum antibiotics in pa­
tients with nosocomial SBP (Fiore 2018). Only one of the in­
cluded studies in this review included solely people with noso­
comial SBP (Piano 2016). There was no evidence of a differ­
ence in any of the outcomes between the meropenem plus dap­
tomycin versus ceftazidime group in this trial. However, this was 
a small trial and included only 31 participants, indicating that 
clinically important benefits or harms are possible in this compar­
ison. Therefore, our conclusions are that there is significant un­
certainty about whether broad-spectrum antibiotics (meropenem 
plus daptomycin) are better than third-generation cephalosporins 
(ceftazidime) in the treatment of nosocomial SBP. 
A U T H O R S ’ C O N C L U S I O N S 
Implications for practice 
Short-term mortality after spontaneous bacterial peritonitis (SBP) 
is high (around 25%). There is significant uncertainty about which 
antibiotic therapy is better in people with SBP. The majority of the 
randomised clinical trials used third-generation cephalosporins, 
such as intravenous ceftriaxone or cefotaxime as one of the inter­
ventions. 
Implications for research 
Further well-designed randomised clinical trials are necessary. 
Some aspects of the design of the randomised clinical trials should 
be as follows. 
• Study design 
◦ Placebo-controlled, parallel, randomised clinical trial 
• Participants 
◦ People with cirrhosis and SBP 
• Intervention 
◦ Not identified from this network meta-analysis. This 
could be one of the newer broad-spectrum antibiotics (or 
combination of antibiotics) or oral third-generation 
cephalosporins or oral ciprofloxacin. 
• Control 
◦ Intravenous ceftriaxone or cefotaxime until at least 
resolution of SBP or availability of culture results. 
• Outcomes 
◦ Primary outcome: short-term mortality (90-day all-
cause mortality) 
◦ Secondary outcomes: health-related quality of life, 
adverse events, resolution of SBP, and resource utilisation 
measures including length of hospital stay 
◦ Minimum length of follow-up: 90 days 
• Sample size: please see Discussion. 
Trials need to be conducted and reported according to the 
SPIRIT (Standard Protocol Items: Recommendations for Inter­
ventional Trials) statement (Chan 2013), and CONSORT state­
ment (Schulz 2010). 
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Unclear risk Comment: this information was not available. 
C H A R A C T E R I S T I C S O F S T U D I E S 
Characteristics of included studies [ordered by study ID] 
Abd-Elsalam 2016 
Randomised clinical trial 
Country: Egypt 
Number randomised: not stated 
Post-randomisation dropouts: not stated 
Revised sample size: not stated 
Average age: not stated 
Females: not stated 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: not stated 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.25 
Years of recruitment: 2014 
Inclusion criteria 
Methods 
• First episode of SBP 
Participants 
Interventions Participants were randomly assigned to two groups 
Group 1: cefotaxime (n = not stated) 
Further details: cefotaxime 2 gm twice/day (route and duration not stated clearly, but 
appears to be 5 days or 1 week) 
Group 2: ceftriaxone (n = not stated) 
Further details: ceftriaxone 2 gm once/day (route duration not stated clearly, but appears 
to be 5 days or 1 week) 
Total number of participants and number of participants in each group was not reported 
Outcomes None of the outcomes of interest were reported. 
Notes Attempts were made to contact the authors in December 2018; there were no replies 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Allocation concealment (selection bias) Unclear risk Comment: this information was not available. 
Risk of bias 
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Abd-Elsalam 2016 (Continued) 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Incomplete outcome data (attrition bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Selective reporting (reporting bias) High Comment: a prepublished protocol was not available, but 
the authors do not report routinely measured clinical out­
comes adequately 
Other bias Comment: no other bias was noted. 
risk 
Ahmed Ather Ch 2014 
Methods 
Participants Country: Pakistan 
Number randomised: 240 
Post-randomisation dropouts: not stated 
Revised sample size: 240 
Average age: 44 years 
Females: 67 (27.9%). 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: not stated 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.25 
Years of recruitment: 2011 
Exclusion criteria 
• Patients with haemorrhagic or malignant ascites 
• Secondary peritonitis 
• Tuberculosis peritonitis 
• Hepatocellular carcinoma 
• Diabetes mellitus 
Interventions Participants were randomly assigned to two groups 
Group 1: ciprofloxacin (n = 120) 
Further details: ciprofloxacin 200 mg IV twice/day for 5 days 
Group 2: ceftriaxone (n = 120) 
Further details: ceftriaxone 1 gm IV twice/day for 5 days 
Randomised clinical trial 
Low risk 
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Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Incomplete outcome data (attrition bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Selective reporting (reporting bias) High risk 
Other bias Low risk Comment: no other bias was noted. 
Ahmed Ather Ch 2014 (Continued) 
Outcomes Outcomes reported 
• Proportion with recovery from SBP 
Notes Attempts were made to contact the authors in December 2018; there were no replies 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Low risk Quote: “Patients were randomly allocated in two groups 
using random number table” 
Allocation concealment (selection bias) Unclear risk Comment: this information was not available. 
Risk of bias 
Comment: a prepublished protocol was not available, but 
the authors do not report routinely measured clinical out­
comes adequately 
Angeli 2006 
Methods Randomised clinical trial 
Participants Country: Italy 
Number randomised: 116 
Post-randomisation dropouts: 0 
Revised sample size: 116 
Average age: 60 years 
Females: 48 (41.4%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): both 
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Quote: “Randomisation was performed with sealed en­
velopes containing treatment options prepared with random 
numbers generated by the STATISTICA 6.1 software.” 
Quote: “Randomisation was performed with sealed en­
velopes containing treatment options prepared with random 
numbers generated by the STATISTICA 6.1 software.” 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Random sequence generation (selection 
bias) 
Low risk 
Allocation concealment (selection bias) Low risk 
Follow-up in months: 3 
Years of recruitment: not stated 
Exclusion criteria 
• Antibiotic treatment including prophylactic treatment with quinolones within 1 
month of inclusion 
• History of hypersensitivity to quinolones or beta-lactam antibiotics 
• Age < 18 years and > 75 years 
• Evidence of other bacterial or fungal infections 
• Evidence of organic nephropathy 
• Presence of shock 
• Gastrointestinal bleeding 
• Dehydration 
• Hepatocellular carcinoma 
• Cardiac failure 
• Extrahepatic neoplasia 
Interventions Participants were randomly assigned to two groups. 
Group 1: ceftazidime (n = 55) 
Further details: ceftazidime 1 g to 2 g once/day or twice/day depending on creatinine 
levels for 8 days 
Group 2: ciprofloxacin (n = 61) 
Further details: ciprofloxacin 200 mg IV once/day or twice/day depending on serum 
creatinine converted to oral ciprofloxacin 250 mg twice/day to 500 mg twice/day de­
pending on serum creatinine when possible for a total of 8 days 
Outcomes 
Notes 
Bias Authors’ judgement Support for judgement 
Risk of bias 
Outcomes reported 
• Mortality 
• Any adverse events (number of people) 
• Proportion with recovery from SBP 
• Other features of decompensation 
Attempts were made to contact the authors in December 2018; there were no replies 
Angeli 2006 (Continued) 
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Angeli 2006 (Continued) 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Comment: there were no post-randomisation dropouts. 
Selective reporting (reporting bias) Low risk Comment: a prepublished protocol was not available but 
the authors report routinely measured clinical outcomes ad­
equately 
Other bias Low risk Comment: no other bias was noted. 





Number randomised: 45 
Post-randomisation dropouts: 8 
Revised sample size: 37 
Average age: 56 years 
Females: 9 (24.3%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 1 
Years of recruitment: 2000-2002 
Exclusion criteria 
• Allergy to penicillins, cephalosporins or aminoglycoside 
• Expected life expectancy of less than one month 
• Secondary peritonitis or tumour rupture 
• Renal impairment 
• Antibiotic treatment during previous 2 weeks 
Methods 
Participants 
Participants were randomly assigned to two groups. 
Group 1: cefotaxime (n = 19) 
Further details: cefotaxime 1 g IV three times/day for minimum 5 day 
Group 2: amikacin (n = 18) 
Further details: amikacin with plasma level maintained at <= 30 mg/dL after a loading 
dose of 500 mg or 8 mg/Kg depending on weight for a total duration of minimum 5 
days 
Randomised clinical trial 
Interventions 
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Random sequence generation (selection 
bias) 
Allocation concealment (selection bias) 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Incomplete outcome data (attrition bias) 
All outcomes 
Selective reporting (reporting bias) 
Other bias 
Chen 2005 (Continued) 
Outcomes Outcomes reported 
• Mortality 
• Any adverse event (number of people) 
• Proportion with recovery from SBP 
• Other features of decompensation 
• Length of hospital stay 
Attempts were made to contact the authors in December 2018; there were no replies 
Reason for post-randomisation dropouts: other causes of peritonitis, death, discharged 
against medical advice before starting treatment 
Bias 
Notes 




Randomised clinical trial 
Country: Brazil 
Number randomised: 38 
Post-randomisation dropouts: 0 
Revised sample size: 38 
Average age: 54 years 
Females: 16 (42.1%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en-














Comment: this information was not available. 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: there were post-randomisation dropouts which 
were related to the outcomes 
Comment: a prepublished protocol was not available but the 
authors do not report routinely measured clinical outcomes 
adequately 
Comment: no other bias was noted. 
Support for judgement 
40 
Figueiredo 1997 (Continued) 
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: not stated 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): yes 
Follow-up in months: 0.25 
Years of recruitment: not stated 
Exclusion criteria 
• Hypersensitivity to cephalosporins 
• Secondary bacterial peritonitis 
• Severe shock 
• Renal failure 
• Grade III and IV encephalopathy 
• Hypotension 
Participants were randomly assigned to two groups.
 
Group 1: cefixime (n = 20)
 
Further details: cefixime 400 mg/day oral until 2 days after resolution of signs/symptoms/
 
polymorphonuclear count < 250/mm3
 
Group 2: ceftriaxone (n = 18)
 
Further details: ceftriaxone 1g IV twice/day until 2 days after resolution of signs/symp­
toms/polymorphonuclear count < 250/mm3
 
Interventions 
Outcomes Outcomes reported 
• Mortality 
• Proportion with recovery from SBP 
• Treatment costs 
Notes We were unable to locate the current contact details of the author 
Risk of bias 
Bias Authors’ judgement Support for judgement 
Comment: this information was not available. 
Allocation concealment (selection bias) Unclear risk Quote: “Sealed envelope method” 
Comment: further details were not available. 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Random sequence generation (selection 
bias) 
Unclear risk 
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High risk Comment: prepublished protocol was not available but the 
authors do not report routinely measured clinical outcomes 
adequately 
Figueiredo 1997 (Continued) 
Incomplete outcome data (attrition bias) 
All outcomes 
Low risk Comment: there were no post-randomisation dropouts. 
Other bias Low risk Comment: no other bias was noted. 
Gomez-Jimenez 1993 
Selective reporting (reporting bias) 
Open randomised clinical trial Methods 
Country: Spain 
Number randomised: 60 
Post-randomisation dropouts: not stated 
Revised sample size: 60 
Average age: 59 years 
Females: 13 (21.7%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (for example albumin or diuretics): not stated 
Follow-up in months: 0.5 
Years of recruitment: 1987-1990 
Exclusion criteria 
• History of allergy to beta-lactam antibiotics 
• Haemorrhage into ascites 
• Pancreatitis 
• Tuberculous peritonitis 
• Peritoneal carcinomatosis 
Participants 
Interventions Participants were randomly assigned to two groups. 
Group 1: cefonicid (n = 30) 
Further details: cefonicid 2g IV twice/day for 10 or 4 days after becoming afebrile, 
whichever was shortest. 
Group 2: ceftriaxone (n = 30) 
Further details: ceftriaxone 2g IV once/day for 10 or 4 days after becoming afebrile, 
whichever was shortest 
• Mortality 
Outcomes Outcomes reported 
• Any adverse event (number of people) 
• Proportion with recovery from SBP 
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Blinding of participants and personnel 
(performance bias) 
All outcomes 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Incomplete outcome data (attrition bias) 
All outcomes 







Comment: open clinical trial 
Comment: open clinical trial 
Comment: this information was not available. 
Comment: a prepublished protocol was not available 
but the authors report routinely measured clinical out­
comes adequately 
Comment: no other bias was noted. 
Gomez-Jimenez 1993 (Continued) 
Notes We were unable to locate the current contact details of the author 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment (selection bias) Unclear risk Comment: this information was not available. 




Open randomised clinical trial 
Country: India 
Number randomised: 175 
Post-randomisation dropouts: 0 
Revised sample size: 175 
Average age: 49 years 
Females: 32 (18.3%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): both 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 3 
Years of recruitment: 2012-2014 
Inclusion criteria (if at least one of the following conditions is met) 
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Jindal 2016 (Continued) 
• No response at 48 hours on 3rd generation cephalosporins 
• Current or recent (within 3 months) infection with 3rd generation cephalosporin­
resistant bacteria 
• New onset SBP detected after 48 hours of hospitalisation 
Exclusion criteria 
• Pregnant females 
• Secondary peritonitis 
• Tubercular or fungal peritonitis 
• Advanced hepatocellular carcinoma 
• Human immunodeficiency virus infection 
• Patients on immunosuppressive therapy 
• Patients who had undergone liver transplantation 
Interventions Participants were randomly assigned to two groups. 
Group 1: cefepime (n = 88) 
Further details: cefepime 2 g IV twice/day for 5 days 
Group 2: imipenem (n = 87) 
Further details: imipenem 1 g IV three times/day for 5 days 
Outcomes Outcomes reported 
• Mortality 
• Any adverse events (number of events) 
• Proportion with recovery from SBP 
• Other features of decompensation 
Notes Attempts were made to contact the authors in December 2018; there were no replies 
Risk of bias 
Bias Authors’ judgement 
Random sequence generation (selection 
bias) 
Unclear risk 
Allocation concealment (selection bias) Unclear risk 








Incomplete outcome data (attrition bias) 
All outcomes 
Low risk 
Support for judgement 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: open clinical trial 
Comment: open clinical trial 
Comment: there were no post-randomisation drop­
outs. 









• Proportion with recovery from SBP 
• Other features of decompensation 
• Length of hospital stay 
Jindal 2016 (Continued) 
Selective reporting (reporting bias) Low risk 
Other bias Low risk 
Comment: a prepublished protocol was not available 
but the authors report routinely measured clinical out­
comes adequately 
Comment: no other bias was noted. 
Navasa 1996 
Randomised clinical trial 
Country: Spain 
Number randomised: 132 
Post-randomisation dropouts: 9 
Revised sample size: 123 
Average age: 59 years 
Females: 44 (35.8%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): both 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.5 
Years of recruitment: 1992-1994 
Exclusion criteria 
Methods 
• Absence of severe complications at infection diagnosis, i.e. shock, gastrointestinal 
haemorrhage, renal impairment or grade II-IV hepatic encephalopathy 
• Antibiotic treatment within 2 weeks before inclusion 
• History of hypersensitivity to quinolones or beta-lactam antibiotics 
Participants 
Interventions Participants were randomly assigned to two groups. 
Group 1: ofloxacin (n = 64) 
Further details: ofloxacin 100 mg/day to 800 mg/day depending upon creatinine levels 
(4 days to 2 weeks) 
Group 2: cefotaxime (n = 59) 
Further details: cefotaxime 1 g/day to 8 g/day depending upon creatinine levels (4 days 
to 2 weeks) 
Outcomes 
Notes We were unable to locate the current contact details of the author 
Reason for post-randomisation dropouts: secondary peritonitis, voluntary dropout 
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Blinding of participants and personnel 
(performance bias) 
All outcomes 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Incomplete outcome data (attrition bias) 
All outcomes 







Navasa 1996 (Continued) 
Risk of bias 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Low risk Quote: “Randomization was performed with sealed en­
velopes containing the treatment options prepared with ran­
dom numbers generated by the SAS statistical package (SAS 
Institute Inc., Cary, NC)” 
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed with sealed en­
velopes containing the treatment options prepared with ran­
dom numbers generated by the SAS statistical package (SAS 
Institute Inc., Cary, NC)” 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: there were post-randomisation dropouts; it is not 
clear whether this was related to treatment and/or outcomes 
Comment: a prepublished protocol was not available but 
the authors report routinely measured clinical outcomes ad­
Comment: no other bias was noted. 
equately 
Piano 2016 
Methods Randomised clinical trial 
Participants Country: Italy 
Number randomised: 32 
Post-randomisation dropouts: 1 
Revised sample size: 31 
Average age: 60 years 
Females: 12 (38.7%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: both 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
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Follow-up in months: 3 
Years of recruitment: 2011-2014 
Inclusion criteria 
• Nosocomial SBP 
Exclusion criteria 
• Secondary peritonitis 
• Onset of infection ≤ 72 hours from hospitalisation 
• Abdominal surgery in the previous 4 weeks 
• Hepatocellular carcinoma beyond the Milan Criteria 
• Congestive heart failure and/or respiratory failure 
• Treatment with third-generation cephalosporins, carbapenems or daptomycin at 
the time of diagnosis of SBP 
• Isolation of bacteria resistant to third-generation cephalosporins, carbapenems 
and/or daptomycin in cultures performed in the previous 7 days 
• Allergy to ceftazidime, meropenem and/or daptomycin 
Interventions Participants were randomly assigned to two groups. 
Group 1: ceftazidime (n = 16) 
Further details: ceftazidime 2 g/day to 6 g/day depending on glomerular filtration rate 
for at least 7 days 
Group 2: meropenem + daptomycin (n = 15) 
Further details: meropenem 0.5 g to 3 g/day plus daptomycin 3 mg/Kg/day to 6 mg/ 
Kg/day depending on glomerular filtration rate for at least 7 days 
Outcomes Outcomes reported 
• Mortality 
• Serious adverse events (number of people) 
• Any adverse events (number of people) 
• Liver transplantation 
• Proportion with recovery from SBP 
• Other features of decompensation 
Attempts were made to contact the authors in December 2018; there were no replies 
Reason for post-randomisation dropout: secondary peritonitis 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Low risk Quote: “Randomization was performed using consecutively 
numbered, computer-generated, sealed, opaque envelopes 
containing the treatment assigned.” 
Allocation concealment (selection bias) Low risk Quote: “Randomization was performed using consecutively 
numbered, computer-generated, sealed, opaque envelopes 
containing the treatment assigned.” 
Notes 
Risk of bias 
Piano 2016 (Continued) 
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Piano 2016 (Continued) 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Quote: “Independent laboratory examiners, blinded to as­
signed treatment, manually assessed the ascitic fluid PMN 
count” 
Comment: it is not clear whether patients and healthcare 
providers were blinded 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Quote: “Independent laboratory examiners, blinded to as­
signed treatment, manually assessed the ascitic fluid PMN 
count” 
Comment: it is not clear whether patients and healthcare 
providers were blinded 
Incomplete outcome data (attrition bias) 
All outcomes 
Unclear risk Comment: there were post-randomisation dropouts; it is not 
clear whether this was related to treatment and/or outcomes 
Comment: a prepublished protocol was not available but 
the authors report routinely measured clinical outcomes ad­
equately 
Other bias Low risk Comment: no other bias was noted. 
Rastegar 1998 
Selective reporting (reporting bias) Low risk 
Methods 
Participants Country: Iran 
Number randomised: 20 
Post-randomisation dropouts: not stated 
Revised sample size: 20 
Average age: 42 years 
Females: 5 (25%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.25 
Years of recruitment: not stated 
Inclusion and exclusion criteria: not stated 
Interventions Participants were randomly assigned to two groups. 
Group 1: ampicillin + gentamycin (n = 9) 
Further details: ampicillin IV 4 g/day plus gentamycin 40 to 60 mg IV three times/day 
for 10 to 14 days 
Group 2: pefloxacin (n = 11) 
Further details: pefloxacin 400 mg/36 hours for 7 to 10 days 
Randomised clinical trial 
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Rastegar 1998 (Continued) 
Outcomes Outcomes reported 
• Mortality 
We were unable to locate the current contact details of the author 













Incomplete outcome data (attrition bias) 
All outcomes 
Unclear risk 
Selective reporting (reporting bias) High risk 
Other bias Low risk 
Notes 
Risk of bias 
Bias 
Random sequence generation (selection 
bias) 
Allocation concealment (selection bias) 
Support for judgement 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: this information was not available. 
Comment: a prepublished protocol was not available but the 
authors do not report routinely measured clinical outcomes 
adequately 




Randomised clinical trial 
Country: Turkey 
Number randomised: 53 
Post-randomisation dropouts: 0 
Revised sample size: 53 
Average age: 46 years 
Females: 19 (35.8%) 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): both 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: both 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
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Tuncer 2003 (Continued) 
Other causes for cirrhosis: both 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.25 
Years of recruitment: not stated 
Exclusion criteria 
• Hypersensitivity to quinolones or cephalosporins 
• Recent antibiotic use 
• Systemic infections 
• Secondary peritonitis 
Participants were randomly assigned to three groups.
 
Group 1: cirpofloxacin (n = 16)
 
Further details: ciprofloxacin 500 mg oral twice/day for 5 days
 
Group 2: cefotaxime (n = 18)
 
Further details: cefotaxime 2 g IV three times/day for 5 days
 
Group 3: ceftriaxone (n = 19)
 
Further details: ceftriaxone 2 g/day IV for 5 days
 
Interventions 
Outcomes Outcome reported 
• Mortality 
• Any adverse events ( number of people) 
• Proportion with recovery from SBP 
• Other features of decompensation 
• Treatment costs 
Notes Attempts were made to contact the authors in December 2018; there were no replies 
Follow-up information was not available but the follow-up was probably until the end of 
hospitalisation. Although the authors excluded 3 patients from the analysis, these have 
been included for all outcomes other than complications and decompensated cirrhosis 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment (selection bias) Unclear risk Comment: this information was not available. 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Risk of bias 
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Tuncer 2003 (Continued) 
Incomplete outcome data (attrition bias) 
All outcomes 
Low risk Comment: all patients were included in the analysis of mor­
tality and SBP resolution. There were post-randomisation 
dropouts related to the treatment and outcome for remain­
ing outcomes; therefore risk of bias is high for these out­
comes 
Comment: a prepublished protocol was not available but 
the authors report routinely measured clinical outcomes ad­
equately 
Other bias Low risk Comment: no other bias was noted. 
Yim 2017 
Selective reporting (reporting bias) Low risk 
Country: South Korea 
Number randomised: 261 
Post-randomisation dropouts: not stated 
Revised sample size: 261 
Average age: not stated 
Females: not stated 
Presence of other features of decompensation (hepatorenal syndrome, hepatic en­
cephalopathy, or variceal bleeding): not stated 
Alcohol-related cirrhosis: not stated 
Viral-related cirrhosis: not stated 
Autoimmune disease-related cirrhosis (e.g. PSC, PBC, AIH): not stated 
Other causes for cirrhosis: not stated 
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated 
Follow-up in months: 0.25 
Years of recruitment: 2007-2016 
Exclusion criteria 
• Allergic to third-generation cephalosporins or quinolones 
• Antibiotics within 2 weeks 
• Open abdominal surgery within 4 weeks 
• Evidence of secondary peritonitis, intra-abdominal haemorrhage, pancreatitis, 
tuberculous peritonitis or peritoneal carcinomatosis 
• Hepatocellular carcinoma with portal vein thrombosis 
• Pregnant women 
• HIV positivity 
Methods 
Participants 
Participants were randomly assigned to three groups. 
Group 1: ciprofloxacin (n = not stated) 
Further details: (route and duration not stated) 
Group 2: cefotaxime (n = not stated) 
Further details: (route and duration not stated) 
Group 3: ceftriaxone (n = not stated) 
Further details: (route and duration not stated) 
Randomised clinical trial 
Interventions 
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Yim 2017 (Continued) 
AIH: autoimmune hepatitis 
IV: intravenous 
PBC: primary biliary cholangitis 
PSC: primary sclerosing cholangitis 
SBP: spontaneous bacterial peritonitis 
Outcomes None of the outcomes of interest were reported. 
Attempts were made to contact the authors in December 2018; there were no replies 
Risk of bias 
Bias Authors’ judgement Support for judgement 
Random sequence generation (selection 
bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment (selection bias) Unclear risk Comment: this information was not available. 
Blinding of participants and personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Blinding of outcome assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Incomplete outcome data (attrition bias) 
All outcomes 
Unclear risk Comment: this information was not available. 
Selective reporting (reporting bias) High risk Comment: a prepublished protocol was not available but the 
authors do not report routinely measured clinical outcomes 
adequately 
Other bias Low risk Comment: no other bias was noted. 
Number of participants in each group not stated 
Notes 


















It includes infections other than SBP and no separate data are available 
It includes infections other than SBP and no separate data are available 
This is a review. 
This is not a randomised clinical trial. 
This is a review. 
This is a review. 
It includes infections other than SBP and no separate data are available 
This is not a randomised clinical trial. 
This is not a randomised clinical trial. 
Characteristics of excluded studies [ordered by study ID] 
Reason for exclusion 
Only one group was allowed to receive other antibiotics in addition to the randomised treatment 
Badawy 2013 Randomisation was performed after matching to similar patients; the allocation of the second person can be predicted 
with 100% accuracy 
SBP: spontaneous bacterial peritonitis 




Randomised clinical trial 
Participants People with cirrhosis and spontaneous bacterial peritonitis 
Oral antibiotics versus intravenous antibiotics 
Outcomes Mortality 
Notes	 It was not clear whether a single oral antibiotic was compared with intravenous antibiotic or a group of oral antibiotics 
was compared with a group of intravenous antibiotics or whether the same antibiotic was compared by oral and 
intravenous antibiotics. We made attempts to clarify this information from the authors in December 2018, but we 
did not receive any replies 
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A D D I T I O N A L T A B L E S 
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Table 1. Characteristics and potential effect modifiers of included studies ordered by comparison (Continued) 
tion 
























































































































Unclear High Unclear 
Low Low Unclear 
Unclear 
Unclear High Unclear 
Low Low Unclear 
Unclear High Unclear 
































Low Low Unclear Unclear 
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Table 3. Model fit 
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Table 3. Model fit (Continued) 
pD 10.83 10.77 10.83 
Length of hospital stay Fixed-effect model Random-effects model Inconsistency model 
Dbar 14.39 14.38 14.39 
DIC 18.39 18.36 18.39 
pD 3.999 3.986 3.999 
Abbreviations 
Dbar: posterior mean of deviance; pD: effective number of parameters or leverage; DIC: deviance information criteria 
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Abbreviations: SBP: spontaneous bacterial peritonitis 
The table provides the effect estimates (proportion of people with any adverse events; hazard ratio for all-cause mortality and spontaneous 
resolution for SBP; rate ratio for other decompensation; and mean difference in days for length of hospital stay) of each pairwise 
comparison for the different outcomes. The top half of the table indicates the effect estimates from the direct comparisons. The bottom 
half of the table indicates the effect estimates from the network meta-analysis. For network meta-analysis, to identify the effect estimate 
of a comparison, say A versus B, look at the cell that occupies the row corresponding to intervention A and the column corresponding 
to intervention B for the direct effect estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B 
and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the treatment effect of A 
versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies the column corresponding to intervention 
A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty, look at the column corresponding 
to intervention B and the row corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A 
versus B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no direct comparison. 
There were no significant differences in the effect estimates for any of the comparisons in any of the outcomes for which network meta-
analysis could be performed. 
A P P E N D I C E S 
Appendix 1. Search strategies 
Database 
Central Register of Controlled Trials 
(CENTRAL) in the Cochrane Library 
Issue 11, 2018 #1 (spontaneous near/3 bacterial near/3 peritonitis) 
#2 MeSH descriptor: [Liver Cirrhosis] explode all 
trees 
#3 ((hepatic or liver) and (fibrosis or cirrhosis or 
cirrhotic)) 
#4 #2 or #3 
#5 #1 and #4 
MEDLINE Ovid January 1947 to November 2018 1. (spontaneous adj3 bacterial adj3 peritonitis).ti, 
ab. 
2. exp Liver Cirrhosis/ 
3. ((hepatic or liver) and (fibrosis or cirrhosis or 
cirrhotic)).ti,ab 
4. 2 or 3 
Time span Search strategy 









Science Citation Index Expanded (Web of 
Science) 
World Health Organization International 
Clinical Trials Registry Platform ( 
apps.who.int/trialsearch/Default.aspx) 
ClinicalTrials.gov 
5. 1 and 4 
6. randomized controlled trial.pt. 
7. controlled clinical trial.pt. 
8. randomized.ab. 
9. placebo.ab. 




14. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp animals/ not humans.sh. 
16. 14 not 15 
17. 5 and 16 
January 1974 to November 2018 
January 1945 to November 2018 #1 TS=(spontaneous near/3 bacterial near/3 peri­
tonitis) 
#2 TS=((hepatic or liver) and (fibrosis or cirrhosis 
or cirrhotic)) 
#3 TS=(random* OR rct* OR crossover OR masked 
OR blind* OR placebo* OR meta-analysis OR sys­
tematic review* OR meta-analys*) 
#4 #1 AND #2 AND #3 
November 2018 spontaneous bacterial peritonitis 
November 2018 cirrhosis | Interventional Studies |Spontaneous Bac­
terial Peritonitis | Phase 2, 3, 4 
1. exp bacterial peritonitis/
 




3. 1 or 2
 
4. exp liver cirrhosis/
 




6. 4 or 5
 
7. 3 and 6
 
8. exp crossover-procedure/ or exp double-blind
 




9. (((((random* or factorial* or crossover* or cross
 
over* or cross-over* or placebo* or double*) adj
 




10. 8 or 9
 
11. 7 and 10
 








European Medical Agency 
(www.ema.europa.eu/ema/) and US Food 
and Drug Administration (www.fda.gov) 
November 2018 spontaneous bacterial peritonitis 
C O N T R I B U T I O N S O F A U T H O R S 
Protocol 
Conceiving the protocol: KG 
Designing the protocol: KG 
Co-ordinating the protocol: KG 
Designing search strategies: KG 
Writing the protocol: KG 
Providing general advice on the protocol: ET, PW 
Securing funding for the protocol: KG 
Performing previous work that was the foundation of the current study: not applicable 
Review 
Co-ordinating the review: KG 
Study selection: KG, LP, AB, MP, DR 
Data extraction: KG, LP 
Writing the review: KG with contribution of LP for characteristics and ’Risk of bias’ tables 
Providing advice on the review: EJM, PW, AJS, NJC, NH, SF, DT, CSP, BRD, ET 
Securing funding for the review: KG 
D E C L A R A T I O N S O F I N T E R E S T 
None known for any of the authors. 
S O U R C E S O F S U P P O R T 
Internal sources 
• University College London, UK. 
Writing equipment, software, etc. 








• National Institute for Health Research, UK. 
Payment for writing reviews, writing equipment, software 
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W 
1. We did not perform Trial Sequential Analysis (TSA), as the risk of false positive results with Bayesian meta-analysis is probably 
less or at least equivalent to TSA. 
2. We used the latest guidance from the GRADE Working group (Yepes-Nunez 2019), rather than the previous guidance (Puhan 
2014), for presenting the ’Summary of findings’ table. 
3. The trials did not report the proportion of people with other episodes of decompensation but reported the number of episodes 
of decompensation. Therefore, we treated this as a count outcome and used the Poisson likelihood to calculate the rate ratio. 
4. We used ceftriaxone rather than cefotaxime as the control group, since ceftriaxone was the commonest control group in the trials. 
5. In the absence of a protocol published prior to the start of the study, we have classified the risk of bias as low for selective 
reporting bias only when mortality, adverse events, and spontaneous bacterial peritonitis (SBP) were reported, as we anticipated these 
outcomes to be routinely measured in clinical trials of this nature. 
6. We used 30,000 iterations as a minimum for burn-in. 
7. We did not present some information because of the concern about the misinterpretation of the results. We have highlighted this 
clearly within the text of the review along with the reasons for not presenting them. 
N O T E S 
The methods section of this protocol is based on a standard Cochrane Hepato-Biliary Group template incorporating advice by the 
Complex Reviews Support Unit for a network meta-analysis protocol (Best 2018). 
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